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ABSTRACT 
Spermatogenesis is a highly regulated, cyclical process where sperm are 
constantly produced. Previous work characterizing male rodents maintained on a 
Vitamin A Deficient diet has demonstrated that retinoic acid (RA) governs two 
transitions during mammalian spermatogenesis. These germ cell transitions include the 
transition from undifferentiated spermatogonia to differentiating spermatogonia, which 
continue to proliferate mitotically, and the transition from mitosis to meiosis. This work 
led to questions about the mechanisms through which RA governs these transitions. 
 Here I will present my findings demonstrating that Stra8, previously 
demonstrated to be a RA-induced gene, is a target gene of RA in both the transition 
from undifferentiated spermatogonia to differentiating spermatogonia and the transition 
from mitosis to meiosis. I conclude that RA inducing Stra8 is the mechanism that 
regulates these developmental transitions. The architecture of germ cell development in 
the rodent testis is such that these two RA-governed transitions occur in immediate 
physical proximity, suggesting the possibility that the RA inducing Stra8 mechanism 
could regulate both transitions simultaneously. I conclude that this mechanism could 
play a part in the regulation of the seminiferous cycle during spermatogenesis.  
In the appendices I will also present my findings that demonstrate Stra8 functions 
in testicular germ cell tumors. I conclude that Stra8 function in the transition from 
undifferentiated spermatogonia to differentiating spermatogonia acts as a tumor 
suppressor for seminoma tumors. In contrast, I find that Stra8 is required for testicular 
teratomas to form, indicating a role for Stra8 in the formation of these tumors.  
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Introduction 
 Germ cells act as a link between generations, passing down genetic information 
from parent to child in the form of gametes. The mother contributes her genetic 
information through the egg, the female gamete, while the father contributes his through 
sperm, the male gamete. This introduction will discuss the developmental process of 
sperm production in males. In addition a discussion of a consequence of disrupted 
development of male germ cells, testicular germ cell tumors, will be covered. 
 
Spermatogenesis 
 Sperm are the vehicle by which males transmit genetic information to the next 
generation. The developmental process of producing sperm is essential for preservation 
of the species. After puberty, adult men produce approximately 100 million sperm per 
day, or approximately 1000 sperm per heartbeat(1). This constant production of sperm 
occurs within the testis through an intricate and coordinated process called 
spermatogenesis. Spermatogenesis is a highly regulated process consisting of three 
major phases: mitotic expansion of progenitor cells; meiotic division to form haploid 
cells; and cellular differentiation of sperm (Figure 1).  
The progenitor cells are termed spermatogonia, and are divided into 
undifferentiated and differentiating spermatogonia. Among the undifferentiated 
spermatogonia are the testis stem cells, termed spermatogonial stem cells (SSC). The 
SSC, when dividing, undergo two different cellular fates, self-renewal and differentiation. 
Those that undergo self-renewal will remain stem cells, and those that undergo 
differentiation will proceed through a phase of mitotic divisions before entering  
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Figure 1. Development of germ cels during spermatogenesis. Expression during spermatogonial 
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the meiotic phase. Germ cells developing in the meiotic phase are termed 
spermatocytes and will complete two specialized divisions following a single round of 
DNA replication, which will result in haploid cells. These haploid cells are termed 
spermatids, and enter into the phase of cellular differentiation into sperm(2). 
 
Testicular structure and somatic cells in spermatogenesis 
 The structure of the testis is made up of a tough exterior shell known as the 
tunica albuginea, which surrounds a collection of coiled tubes called seminiferous 
tubules (Figure 2). In the spaces between the seminiferous tubules are the interstitial 
cells. Interstitial cells mainly consist of Leydig cells, somatic cells that are responsible 
for the production of testosterone and other androgens necessary for sexual 
development, but also include macrophages and epithelial cells. The seminiferous 
tubules are composed of a surrounding layer of peritubular myoid cells which provide 
structural support to the cells residing within, the germ cells and the Sertoli cells. The 
structure within the tubules is known as the seminiferous epithelium, the integrity of 
which is maintained by the Sertoli cells. At all stages of their differentiation, the germ 
cells are in close contact with the Sertoli cells. The Sertoli cells also form tight junctions 
among themselves, which divides the seminiferous tubules into two compartments, the 
basal compartment and the luminal compartment. The SSC and mitotic spermatogonia 
reside in the basal compartment of the seminiferous tubule, while the remaining germ 
cells reside in the luminal compartment. As preleptotene spermatocytes transition into 
leptotene spermatocytes they translocate to the luminal compartment. (Figure 2)  
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Spatial and temporal organization of spermatogenesis 
 The seminiferous epithelium is a structure highly spatially and temporally 
organized. Any given cross section of a tubule contains a set of associated germ cell 
types (Figure 2). These stereotypic associations are known as stages. These stages are 
identified in tubule cross sections by their distinct morphological characteristics. In mice, 
there are 12 such characterized stages where each stage is represented by a specific 
set of germ cells that are present at a given point along the tubule length at the same 
time. In humans there are six such stages. While cross sections of tubules reveal 
temporal germ cell associations, longitudinal sections reveal stage progression (Figure 
2). Stages progress down the length of the tubule in developmental order creating 
waves of differentiation. This phenomenon is essentially the changing cellular 
associations across space. The combination of these cellular associations across space 
and over time constitutes the seminiferous cycle. 
In mice, the transition of undifferentiated spermatogonia into the first 
differentiating spermatogonia (the first appearance of A1 spermatogonia) occurs every 
8.6 days. The timing of this transition coincides with the release of sperm into the tubule 
lumen and the pre-meiotic DNA replication that takes place in preleptotene 
spermatocytes, signifying entry into meiosis in the same stage. This means that every 
8.6 days, undifferentiated spermatogonia will differentiate at the base of the tubule, 
preleptotene spermatocytes will enter meiosis, and sperm will be released into the 
lumen simultaneously. In mice this is characterized as stage VIII. The net result of this 
asynchronous phased release of sperm occurring along the entire tubule length is the 
continuous production of sperm.  
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 Phase One: Mitotic expansion of progenitors  
 During phase one, the germ cells undergo a series of mitotic divisions that 
expand the germ cell pool. At the start of these divisions the SSCs are established, and 
then maintained. The germ cells also begin further differentiation during this phase that 
prepares them for meiotic division in phase two. In this section, I will discuss the 
establishment, the identity, and the maintenance of SSCs, as well as control over the 
differentiation process that begins during phase one. 
In the male embryonic gonad the germ cells enter into a quiescent G0 state up to 
a few days after birth. In the beginning of the progenitor expansion phase, the germ 
cells transition out of quiescence and into proliferation. In mice, this proliferation begins 
a few days after birth, but it takes several months in livestock, and years in humans and 
other primates(1). Concurrent with the transition to resume mitotic divisions, male germ 
cells either become SSCs or differentiate. These alternative pathways divide the 
spermatogonial population into at least two subpopulations, one establishing the SSC 
and one that differentiates and goes on to form the first round of sperm. This subdivision 
was first proposed based on observations of the kinetics of the first round of 
spermatogenesis. The germ cells appeared to simultaneously establish the stem cell 
pool and form the first differentiating spermatogonia(3), indicating two different 
populations. Confirmation of these sub-populations was obtained by tracing the 
spermatogonial lineage expressing Ngn3. Yoshida et. al, found that germ cells 
produced in the first round of spermatogenesis do not pass through an Ngn3-expressing 
stage, while germ cells produced in all other rounds of spermatogenesis do(4). It is still 
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unclear how the gonocytes are driven towards establishing the SSC versus 
differentiating into the first round of spermatogenesis; however, several factors have 
been identified that are required for SSC self-renewal and maintenance. These factors 
act both within the SSC in SSC-specific and through the surrounding somatic cells. I will 
discuss a few of these factors. 
Within the SSC themselves, two factors have been identified, Zbtb16/Plzf and 
Taf4b, which are both required for SSC self-renewal. Plzf is a transcriptional repressor 
whose expression is restricted to undifferentiated spermatogonia(5, 6). Plzf-deficient 
testes undergo a progressive loss of spermatogonia with age, with no apparent defect in 
somatic cells. The Plzf-deficient germ cells do not retain SSC activity in the presence of 
wildtype somatic cells, indicating a defect intrinsic to SSCs. Recent work has suggested 
a role for Plzf in modulating histone lysine methylation state in undifferentiated 
spermatogonia(7). In addition, Plzf regulates mTORC1, a complex involved in 
coordinating cell growth with growth factors and nutrient availability(8). 
Taf4b (TAF4B RNA polymerase II, TATA box binding protein (TBP)-associated 
factor) is a gonad specific component of the TFIID complex. This complex contains TBP 
(TATA binding protein) and its associated factors which are critically important for core 
promoter recognition and activator-dependent RNA Polymerase II recruitment(9, 10). 
Taf4b is specifically expressed in spermatogonia and spermatids. Taf4b-deficient mice 
are initially fertile, but by three months of age are infertile, despite appearing 
histologically normal. However expression of PLZF is reduced and the weight of the 
Taf4b-deficient testis is 40% that of control testes. By eight months of age the tubules 
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are entirely devoid of germ cells, indicating Taf4b is required for the maintenance of 
SSC population in adult testes(11). 
In addition to these SSC-intrinsic factors, two related factors produced from the 
testicular somatic cells, Gdnf and Etv5/Erm, are required for SSC self-renewal. Gdnf, 
glial cell line derived neurotrophic factor, is produced and secreted by the Sertoli 
cells(12). GDNF functions in germ cells by binding to the subset of undifferentiated 
spermatogonia expressing its receptor complex Gfra1 (glial cell line derived 
neurotrophic factor family receptor alpha) and Ret (13), activating the Ret signaling 
pathway(14). Gdnf is required for SSC maintenance, as Gdnf heterozygous mice lose 
SSC with age, and overexpressing Gdnf in mice leads to the accumulation of 
spermatogonia that are unable to differentiate, leading to the formation of germ cell 
tumors in older mice(15). In addition, Gdnf is required for the self-renewal of SSCs in 
vitro(16-18).  
The relevant downstream targets of Gdnf signaling are an active area of 
research, with three transcription factor genes, Bcl6b, Lhx1, and Erm/Etv5 found thus 
far. Suppression of Bcl6 mRNA by siRNAs results in the loss of SSCs in culture, and 
Bcl6-deficient testes contain some tubules where spermatogenesis is defective (19). 
Knockdown of Lhx1 in cultures of SSC also result in the loss of SSCs in vitro(19), but 
the Lhx1-deficient mice die as neonates, precluding a study of their potential in 
spermatogenesis(20). 
 Erm is a transcription factor mainly expressed in Sertoli cells. Erm-deficient 
testes are deficient in SSC self-renewal, resulting in progressive germ cell depletion and 
tubules containing only Sertoli cells. Expression analysis of Erm-deficient primary Sertoli 
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cells showed a reduction in chemokines Cxcl12 (Sdf-1), Cxcl15 (Lix), and Ccl7 (Mcp3). 
These chemokines are postulated to be the niche signaling molecules that regulate 
SSC self-renewal(21). Gdnf regulates Erm expression in cultured SSCs(19), and Erm 
appears to be required for normal spermatogenesis in both germ cells and Sertoli cells 
(22). 
Another question that remains is the identity of the SSCs. The SSCs are defined 
as cells that self-renew as well as differentiate. These functions are assayed by 
transplantation into a testis depleted of germ cells either by chemotoxic drugs (busulfan) 
or genetic mutation (W/Wv mutant males). Using this assay, each colony of established 
spermatogenesis is derived from a single SSC. Counting the number of colonies gives a 
measure of the number of SSCs injected. This technique has narrowed down SSC 
function within the undifferentiated spermatogonia. The undifferentiated spermatogonia 
are classified into three types; A single (As), A paired (Apr), and A aligned (Aal) (Figure 
1).  
During spermatogenesis, as the germ cells divide they undergo incomplete 
cytokinesis and remain connected by a cytoplasmic bridge (Figure 1). These 
cytoplasmic bridges result in chains of germ cells. The length of the chain is used to 
distinguish the three types of undifferentiated spermatogonia. As are the only germ cell 
type in the testis that are single cells. As divide to form Apr, two connected cells, which 
divide to form Aal, which have chains as short as four cells up to a chain of thirty two 
cells (Figure 1). This led to the hypothesis that As are the stem cells, as Apr and Aal 
based on their cytoplasmic bridges could be considered more differentiated.  
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Recent work has challenged this hypothesis by gene expression analysis and in 
vivo imaging of the undifferentiated spermatogonial population. First, gene expression 
analysis has failed to specify the SSC population. Expression of cell surface markers 
(α6-integrin, β1-integrin, Thy1, CD9, Ep-CAM) that enrich sorted germ cell populations 
for SSC activity in transplantation experiments are not specific to undifferentiated 
spermatogonia(1) and do not subdivide the undifferentiated spermatogonial population 
into SSCs and non-SSCs. Second, most markers expressed specifically in any of the 
undifferentiated spermatogonia are expressed in all three subtypes of undifferentiated 
spermatogonia (Oct4(23), Lin28(24), Plzf(5, 6), Sox3(25), Utf1(26)), with two 
exceptions, Gfrα1 and Ngn3 (Figure 1). Historically GFRα1 expression was used to 
differentiate As and Apr from Aal spermatogonia, but its expression was recently found to 
be a gradient across all three subtypes, with the percentage of GFRα1 expressing cells 
highest in As and lowest in the longest chains of Aal. In contrast the percentage of Ngn3 
expressing cells is lowest in As and highest in the longest chains of Aal. It was 
determined that any Ngn3 expressing cell is destined for differentiation, and that the As 
are not all equivalent, as some As express Ngn3(27). 
Another assumption of the As stem cell model was that of a unidirectional 
differentiation, that is once an Apr, the cell will only advance to an Aal cell. This 
assumption was invalidated by in vivo images of clones fragmenting and reverting back 
to As or shorter chain lengths, sometimes associated with a reversion in gene 
expression. Together these data challenge the As stem cell model, leading to a revised 
model where there are two kinds of stem cells in the testis, “actual” and “potential”. The 
actual stem cells are found within the GFRα1+, Ngn3- cells, and represent the stem cell 
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pool in the normal testicular environment, supporting steady state spermatogenesis. 
The potential stem cells would consist of the cells that retain the ability to self-renew, 
but do not self-renew during steady-state spermatogenesis, waiting to activate this 
potential during regeneration after tissue damage(27). 
At regular intervals, the undifferentiated spermatogonia form the first of six types 
of differentiating spermatogonia, the A1 spermatogonia. The transition from 
undifferentiated to differentiating spermatogonia represents a major regulatory point in 
spermatogenesis and is distinct from all other spermatogonial transitions in that it is not 
a mitotic division. This transition is marked by the first postnatal expression of 
differentiating spermatogonial markers, Kit(28), Ccnd2, and Sohlh2 in the germ cells 
(Figure 1). Several factors are involved in this transition including: RA, Kit/Kitl, Dazl, 
Jsd/Utp14b, Sox3, temperature, and testosterone level. I will discuss a few of these 
factors below. 
RA, retinoic acid, is a metabolite of vitamin A. In vitamin A deficient mice, no RA 
is produced, and only undifferentiated spermatogonia remain, arrested as Aal cells (29). 
An injection of RA causes arrested Aal to re-enter the cell cycle and differentiate into A1 
spermatogonia within twenty-four to forty-eight hours(28, 29). These results indicate that 
RA is required for the transition between undifferentiated and differentiating 
spermatogonia. Zhou et. al. have shown that cultured undifferentiated spermatogonia 
show a robust induction of Stra8 and Kit, genes induced as A1 spermatogonia are 
formed, when treated with RA in culture in the absence of somatic cells, concluding that 
RA can act directly on the germ cells in vitro (30).  
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Investigations of several mutations at the Steel (encoding KITL) and White 
spotting (encoding KIT) loci revealed that defects in KIT/KITL signaling lead to a range 
of severity in spermatogenic failure. KITL/SCF (stem cell factor) is a ligand secreted by 
Sertoli cells in the testis, and KIT, the receptor, is expressed on the surface of germ 
cells(31). Sl17h leads to a splicing defect in the cytoplasmic tail of the protein encoded 
by Kitl(32); Sl17h germ cells only advance to Aal, and despite continued proliferation do 
not accumulate because of increased apoptosis(33). In addition, depleting the testis of 
KIT by injection of a monoclonal antibody against KIT, or a mutation that prevents KIT 
from binding to and activating its target PI3K, also inhibits undifferentiated 
spermatogonia from transitioning to differentiating spermatogonia(34, 35).  
Jsd homozygous male mice are sterile, with a single wave of spermatogenesis 
followed by failure of undifferentiated spermatogonia to differentiate, although 
occasionally more differentiated germ cells are observed. These testes also include 
actively proliferating undifferentiated spermatogonia accompanied by apoptosis. This 
defect was shown to be in the germ cell but not in the intra-tubular somatic environment 
by germ cell transplantation experiments(33, 36). The Jsd mutation results in a small 
rearrangement within the gene Utp14b, a testis-specific retrotransposed copy of the 
ubiquitously expressed X-linked gene Utp14a. Utp14, the yeast homologue, is proposed 
to increase the efficiency of protein production during spermatogenesis in general, or 
more specifically to enable ribosome assembly in male meiotic cells(37, 38), leading to 
the proposal of Utp14b acting in the same way. 
Following the formation of A1 spermatogonia, the cells undergo a series of five 
mitotic divisions. The first three divisions produce A2, A3, and A4 spermatogonia (Figure 
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1). These cells can only be distinguished from A1 spermatogonia and each other by 
their chain lengths, no known expression differences exist, and the chromatin 
morphology of these cells is very similar. When A4 divide, they form the Intermediate 
spermatogonia (Figure 1). These cells have a distinctive chromatin morphology which 
can be determined by hematoxylin staining. In (Intermediate) spermatogonia then divide 
to form type B spermatogonia (Figure 1), which also can be distinguished by their 
chromatin morphology. Despite the differences in chromatin morphology that divide the 
differentiating spermatogonia into three groups (A, In, B), no molecular markers 
distinguish the individual cell types(39), and almost no mutations affect the transitions 
between these cell types. However, one gene, Sohlh2 has been proposed by Hao et. al. 
to act at the transition from A1 to A2 spermatogonia(40). In the Sohlh2-deficient mice, 
they report undifferentiated spermatogonia appear normal, but found reduced numbers 
of In and type B spermatogonia, as well as colonies of dying differentiating A 
spermatogonia. Hao et. al. identified these degenerating colonies as A2 spermatogonia 
accumulating in M phase prior to death. However, since this conclusion is based on 
distinguishing the differentiating type A spermatogonia from each other, for which no 
morphologic or gene expression differences exist, I conclude that it is possible the 
degenerating A spermatogonia are A1 spermatogonia, indicating a block at Aal to A1. In 
support of a block at Aal to A1, the authors reported that the ratio of undifferentiated to 
differentiating spermatogonia was twice the normal level in Sohlh2-deficient testes. The 
spermatogonial defect also occurred prior to KIT expression, as shown by cultured 
Sohlh2-deficient undifferentiated spermatogonia proliferate normally but fail to express 
KIT. As KIT expression begins in late Aal spermatogonia, I conclude that the defect 
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occurred in Aal spermatogonia, and Sohlh2 acts in the transition of Aal spermatogonia 
into A1 spermatogonia.,  
The observation that the majority (or the entirety) of known spermatogonial 
mutations arise at the Aal to A1 transition suggest there is a significance to this 
transition. These results could be taken to mean that transitioning into an A1 
spermatogonia is a main regulatory step, and differentiating spermatogonia serve as 
transit-amplifying cells. Alternatively it could be that whatever differentiation occurs 
during these divisions is preparation for meiotic division, a defect that may not be 
detectable until the cells attempt meiosis. 
 
Phase two: Meiotic division to form haploid germ cells 
Meiosis is a specialized, germline-specific division ultimately resulting in haploid 
gametes. After a single DNA replication, meiotic germ cells undergo cellular division 
twice. The first meiotic division separates homologous chromosome pairs, and the 
second division separates sister chromatid pairs resulting in germ cells with half the 
normal genome content. Type B spermatogonia, the last germ cell type of the mitotic 
expansion phase, divide to give rise to preleptotene spermatocytes. The preleptotene 
spermatocyte is the germ cell that completes the final germ cell DNA replication during 
spermatogenesis, pre-meiotic DNA replication. During DNA replication cohesin 
complexes that link sister chromatids are loaded onto the DNA. During meiosis, these 
cohesin complexes contain specialized meiosis-specific cohesion proteins (Stag3(41), 
Rec8(42), and Smc1b(43)). After this replication event, the preleptotene spermatocyte 
will enter meiotic prophase and become a leptotene spermatocyte. Meiotic prophase 
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consists of four characteristic stages (leptotene, zygotene, pachytene, and diplotene) 
that are easily identified by their chromatin morphology.  
During leptotene, the chromosomes condense from their diffuse state into visible 
strands. In addition, leptotene spermatocytes begin meiotic recombination by forming 
the necessary double strand breaks. Leptotene spermatocytes also begin the assembly 
of the synaptonemal complex, a meiosis-specific complex necessary for synapsis 
(pairing of homologous chromosomes), by loading components of the axial element of 
the synaptonemal complex (SYCP2 and SYCP3(44)) onto their chromosomes. During 
early zygotene, homologous chromosomes pair and synapsis begins. At this point 
spermatocytes load the central element synaptonemal component SYCP1(45).  
Following zygotene, the spermatocytes progress into pachytene. In the mouse 
the pachytene stage lasts for over seven days. During pachytene, crossing over occurs, 
where the chromosomes exchange genetic material. At these sites of exchange 
chiasmata are formed. Also in pachytene, transcription from the X and Y chromosomes 
is silenced via a mechanism known as meiotic sex chromosome inactivation (MSCI). 
During MSCI, the X and Y chromosomes are localized in a distinct nuclear partition 
known as the sex body. The sex body is marked by a phosphorylated histone variant, 
gamma-H2AX, across the entirety of the sex body.  
Following pachytene is the diplotene stage of meiotic prophase. During diplotene 
the synaptonemal complex degrades and the homologous chromosomes begin to 
separate, but are still connected by the chiasmata formed during pachytene. These 
chiasmata connections are not removed until anaphase I. MSCI persists through the 
diplotene stage of meiotic prophase and through the second division. In mice, the 
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progression from meiotic metaphase I through the second meiotic division occurs very 
rapidly. The products of these divisions are four haploid cells termed round spermatids. 
 
Phase three: Cellular differentiation of sperm 
Round spermatids must undergo a series of characteristic changes that will 
transform them from their initial round appearance into the elongated form of a sperm 
cell. This process, termed spermiogenesis, takes two weeks to complete in mice. 
Spermiogenesis involves several differentiation steps that are specific to male germ 
cells. One of the first steps is initiation of acrosome formation. As a result of this process 
the nucleus migrates to the surface of the cell, which establishes cell polarity, 
separating the regions which develop as the sperm head and the tail. Another step 
during spermiogenesis is replacing the histones in the spermatid chromatin. Histones 
are initially replaced by transition proteins, which are themselves replaced by 
protamines. Histone replacement results in a more compacted nucleus, a process 
necessary for chromatin to fit inside the sperm head whose volume is smaller than a 
spermatid nucleus. 
Once cellular polarity is established in the spermatids, the centrioles migrate to 
the surface of the cell, where the production of a flagellum begins. The production of the 
flagellum is completed while the germ cells are still residing in the testis; however, these 
cells are still non-motile, as the flagellum does not function. A final process during 
spermiogenesis is the overall elimination of cytoplasmic volume. The spermatids will 
lose at least 25% of cellular volume as they develop into mature sperm. Following their 
maturation in the testis, during a process known as spermiation, sperm are released 
22
and travel through the efferent ducts (also known as the rete testes). Once in the 
epididymis, a coat of glycoproteins is added to the acrosome to prevent activation of the 
acrosome reaction. Once the sperm interact with the female reproductive tract, this 
glycoprotein coat is eliminated, a process called capacitation, and the sperm become 
hyper motile. These sperm cells are now ready to interact with the zona pellucida of the 
egg and initiate fertilization. 
 
Vitamin A and spermatogenesis 
Vitamin A is required for fertility.  Studies using vitamin A-deficient (VAD) rodents have 
shown a requirement for vitamin A at the transition from undifferentiated spermatogonia 
to differentiating A1 spermatogonia(29, 46), and the entry into meiosis(46, 47). In 
general, the actions of vitamin A in the testis are mediated by its transport, metabolism, 
degradation of retinoids (compounds chemically related to vitamin A), and activation of 
its nuclear receptors(48). Retinoic acid (RA) is the oxidized active form of vitamin A, but 
is poorly transported via serum, so in general the oxidation of dietary vitamin A (retinol) 
takes places in target tissues. Retinol is stored in the liver and transported to target 
tissues(49) that express the required intracellular binding proteins and retinoid 
metabolism enzymes(50). The target tissues then regulate the local production and 
degradation of RA.  
 The biosynthetic pathway for generating RA from retinol involves two oxidation 
steps (Figure 3). The first step generates retinaldehyde (retinal), which is then oxidized 
to generate RA(49). This step is catalyzed by retinaldehyde dehydrogenases. The 
cytochrome p450 enzyme, family 26 (Cyp26) enzymes hydroxylate RA and inactive it,  
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negatively regulating the local level of RA(51). Within cells, RA binds to two families of 
intracellular receptors termed RA receptors (RARs) and retinoid X receptors (RXRs).  
These receptors act as homo- and heterodimers, regulating gene expression by binding 
to specific elements in the promoter regions of genes under the control of vitamin A.  
There are many isoforms of RAR and RXR in the various testicular cell types at 
different developmental stages; however it appears that RA acts primarily via the 
actions of RARα in Sertoli cells and RXRβ, based on genetic deletion studies of 
individual receptors. Rarα-deficient mice are sterile, but Rarα-deficient cultured SSCs 
transplanted into a Rarα-sufficient somatic testis are able to progress through 
spermatogenesis normally(52), suggesting that Sertoli cell expression of Rarα is critical 
for spermatogenesis. In support of this, deletion of Rarα specifically in Sertoli cells 
recapitulates the phenotype of Rarα-deficient mice, indicating that the functions of Rarα 
are Sertoli cell autonomous(53). In addition, deletion of all the RAR and RXR isoforms 
specifically in Sertoli cells has an identical phenotype to deletion of Rarα alone(53). 
Deletion of Rxrβ leads to a failure to release spermatids and testis degeneration(54).   
In contrast to Rarα and Rxrβ, individual deletion of the isoforms Rarβ, Rxrγ does 
not affect spermatogenesis. Deletion of Rarγ does results in sterility, however these 
effects were found to result from obstruction in the epididymal lumen, and not to a 
defect in the germ cells directly(55). The effect of Rxrα deletion in the testis could not be 
analyzed because the mutants die in utero, precluding any analysis(55). These results 
lead to the conclusion that RA acts primarily through Rarα and Rxrβ in the testis. 
 
Stra8  
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A screen for RA responsive genes led to the cloning of Stra8. Oulad-Abdelghani 
et. al., treated F19 carcinoma cells with RA, and cloned and characterized the induced 
genes. One such RA responsive gene, Stra8, was originally characterized as a male 
germ cell specific gene, with expression specific to premeiotic germ cells(56). The male 
specific expression was later expanded to both sexes in a study characterizing 
expression differences between the germ cells in embryonic ovaries and testes. Using 
cDNA subtraction to find genes expressed specifically in the embryonic germ cells of 
either sex, Stra8 was shown to be expressed in the embryonic ovarian germ cells just 
prior to meiotic entry, and not to be expressed in the embryonic testicular germ 
cells(57). Further support of Stra8’s expression in embryonic ovarian germ cells came 
from a study of Stra8-deficient embryonic ovaries. Characterization of Stra8-deficient 
embryonic ovaries revealed a requirement for Stra8 in ovarian germ cells to enter 
meiosis, including a requirement for pre-meiotic DNA replication(58). Stra8 is also 
expressed in trophoblast giant cells(59), but there does not appear to be any 
consequence to Stra8’s absence in these cells(58). Stra8 transcripts are present in both 
embryonic ovaries(60) and adult testes(61) in humans.  
Further characterization of Stra8’s expression in the postnatal mouse testes has 
shown that while all premeiotic cells express at least low levels of Stra8 RNA, only a 
subset express STRA8 protein(62), hinting at post-transcriptional control of Stra8 in the 
testis. Another possible source of control over STRA8 function is the localization of the 
protein. STRA8 is localized in both the cytoplasm and nucleus(62, 63), and it has been 
shown in vitro that STRA8 is actively shuttled into and out of the nucleus with functional 
nuclear export and nuclear import sequences(63).  
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 Testicular Germ Cell Tumors 
 Germ cell tumors are a group of neoplasms with unusual biology and spectacular 
therapeutic results. In humans, germ cell tumors occur in both the testis and the ovary, 
but we will focus our discussion on those that occur in the testis. Testicular germ cell 
tumor (TGCT) incidence has been increasing, with the lifetime risk at about 1 in 300. In 
the past metastatic TGCTs were a fatal diagnosis, but advancing technology has 
improved the prognosis considerably. Here I will discuss the types of TGCTs in humans, 
the known risk factors, and animal models. 
 
Testicular germ cell tumor incidence and risk peaks 
In the United States, testicular germ cell tumors (TGCTs) are the most common 
cancers affecting young men 25-34 years of age(64, 65). Worldwide the incidence has 
more than doubled in the last 50 years, with an annual increase of 3-6%(66, 67). An 
unusual feature of TGCTs is that in contrast to most cancers where cancer risks 
continually increase with age, the risk for developing subtypes of TGCT increase at 
three different times throughout a male’s life. These three peaks occur in infants less 
than two years of age, around the age of thirty, and around the age of eighty(68). These 
peaks of increased risk suggest that TGCTs may be a special class of cancers that are 
sensitive to developmental points within the germline. 
 In infants, the TGCTs observed are mostly yolk sac tumors, teratomas, and 
teratocarcinomas(68). These three subtypes are all thought to arise from primordial 
germ cells (PGCs) or through an embryonal carcinoma (EC) cell intermediate. PGC is 
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the term used for the population of germ cells from their first establishment as germ 
cells, through their migration to the gonad. Once the PGC enters into the gonad, it is 
known as a gonocyte. EC cells are the malignant version of PGCs(69). Yolk sac tumors 
arise by differentiation of the PGC/EC along an extraembryonic path, whereas 
teratomas result from differentiation along the path of the embryonic germ layers – 
endoderm, mesoderm, and ectoderm. Teratocarcinomas are a mixed tumor type 
consisting of teratomas plus undifferentiated EC cells. While teratomas are considered 
benign, the presence of EC cells within teratocarcinomas is associated with the 
potential for distant metastasis(70, 71).  
Teratomas are composed of variable types of tissue that represent one or more 
of the three embryonic germ layers. Teratomas composed of only one of the three 
embryonic germ layers are known as monodermal teratomas. Teratomas are also 
classified as mature or immature. Mature teratomas are composed entirely of well-
differentiated components, whereas immature teratomas contain embryonic or fetal-like 
tissues. Although teratomas form in both children and adults, the mechanism appears 
different. In children teratomas are the second most common, making up 14% of 
TGCTs. In adults a pure teratoma is uncommon, yet teratomas are present in 50% of 
TGCTs that contain multiple TGCT subtypes in adults. In addition, most teratomas in 
children are exclusively composed of mature tissues while most teratomas in adults are 
immature. The teratomas that form in adults have a far greater risk of harboring EC cell 
foci than those that form in infants, and so are treated as if they were malignant. 
 The second risk peak of TGCTs, in young adults, are the most common TGCT 
subtype – seminomas – and less commonly are mixed tumors composed of teratomas 
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and yolk sac tumors with EC cells. These TGCTs are associated with presence of 
carcinoma in situ (CIS), a transformed pre-invasive lesion, also referred to as 
intratubular germ cell neoplasia. CIS cells are thought to be a neoplastic version of 
either PGCs or of gonocytes, possibly originating from a delayed or blocked maturation. 
Seminomas are the dominant TGCT, composing 50% of all TGCTs, yet are very 
uncommon in infants. Seminomas are aneuploid, and commonly contain an 
isochromosome of 12p. Those seminomas without a 12p isochromosome contain 
amplified sequences from the 12p region, indicating the importance of these DNA 
sequences to seminoma pathogenesis. 
The third risk peak of TGCTs in older men consists mostly of spermatocytic 
seminomas. Spermatocytic seminomas are histologically very similar to seminomas and 
although they also derive from germ cells, they have little else in common with 
seminomas. Unlike seminomas, spermatocytic seminomas are not associated with CIS 
cells and seldom metastasize. Spermatocytic seminomas are also thought to arise from 
a more mature germ cell than seminomas(72). 
 
Risk factors of testicular germ cell tumors 
 Over the last thirty years, the prevalence of TGCTs has been increasing in 
Europe and North America. In Denmark and Norway, which have the highest rates in 
the world, men have almost a 1% risk of developing a TGCT in their lifetime(73). For 
European-American men in the USA in 2003, 6.36 cases per 100,000 per year were 
reported, a rise of 61% from the reported cases in 1978(74). African-American and 
Asian-American rates have also been increasing. Asian-American rates increased 
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62.8% and African-American rates increased 39.8% between 1978 and 2003(74). 
 In addition to race, other known risk factors for TGCTs include a family history of 
TGCT(75), cryptorchidism(76), testicular dysgenesis(77), and a prior diagnosis of 
TGCT(78-80). Infertility(81), dizygotic twinship(82, 83), testicular atrophy (76, 84), and 
abnormal sex chromosome karyotypes are also associated with TGCT formation. These 
factors all relate to abnormal testicular development, leading to the proposal of TDS or 
testicular dysgenesis syndrome, that includes TGCTs and is caused by both genetic 
and environmental factors(85). The TDS hypothesis proposes that abnormal gonadal 
development (dysgenesis) leads to disturbed testis somatic cell function, resulting in 
reproductive disorders including TGCTs. 
Environmental factors are also thought to play a role in TGCT risk, with research 
focusing on the contribution of estrogenic and anti-androgenic pollutants (endocrine 
disruptors). Men with occupations in the mining, chimney sweeping, and food and 
beverage industries are at higher risk, suggesting that chemical exposure in the 
workplace contributes to TGCT risk.  
 Among the most significant risk factors for TGCTs is a family history of TGCT. 
Sons of affected fathers have a 4 to 6-fold increased risk of developing a TGCT, and 
brothers of an affected sibling have an 8 to 10-fold increased risk(86). These data 
indicate a strong genetic component to TGCT formation, as the familial risk to most 
other cancer classes is 2-fold(87). Despite the strong familial contribution to TGCT, the 
identification of susceptibility genes in humans has been difficult. This difficulty arises 
from the limited number of multigenerational pedigrees that contain several affected 
cases, which is possibly linked to the sterility that results from treatment of a TGCT. The 
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International Testicular Cancer Linkage Consortium has found only tenuous linkages by 
conducting mapping experiments on families(88) that lead to the suggestion that there 
are multiple susceptibility loci acting weakly. Three susceptibility factors have been 
described: gr/gr, KITLG, and SPRY4.  
The gr/gr TGCT risk factor is a 1.6 megabase deletion within the AZFc region of 
Yq11, previously associated with subfertility in hemizygous men(89). This deletion does 
not entirely delete any genes, but rather reduces gene copy number of three genes with 
functions in germ cell survival, development, and differentiation (DAZ, BPY2, CDY1, 
TSPY), suggesting that perturbations in these functions promote TGCT formation. The 
gr/gr deletion is present in 1.3% of unaffected males, but is present in 2% of males with 
a TGCT who lack a family history and 3% of males with a TGCT with a family 
history(90). The gr/gr deletion is considered a rare, low penetrance factor. 
Two independent genome wide association studies for TGCT susceptibility 
alleles found links to KITLG and SPRY4(91, 92). KITLG/stem cell factor (Kitl in mice) is 
the ligand for a receptor tyrosine kinase KIT. In mice, the Kit/Kitl signaling system 
regulates the survival, proliferation, and migration of germ cells in both sexes. Mice 
carrying homozygous deletions of either Kit or Kitl are infertile, because of a failure of 
germ cell development. Heterozygous deletion of KITL coding sequence results in a 
two-fold greater risk of teratoma formation in the spontaneous teratoma mouse 
model(93). Somatic missense mutations or amplifications of KIT are found in 25% of 
human seminomas(94). Paradoxically, these somatic mutations of KIT in human 
seminoma are thought to activate its kinase function, whereas the germline deletions of 
KITL in the mouse model are thought to reduce function.  
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SPRY4 is one of a family of four genes that are implicated as negative regulators 
of the RAS-ERK-MAPK signaling pathway in response to growth factors(95). 
Expression analysis and tumor studies of gastrointestinal stromal tumors have shown 
that when KIT signaling is inhibited by imatinib mesylate, SPRY4 is the most 
significantly downregulated gene. This led to the proposal of a functional relationship 
between KIT and SPRY4(96). 
 
Animal Models of testicular germ cell tumors 
Teratomas: 129 Mouse Teratoma  
Mice from the 129 family of inbred strains spontaneously form TGCTs, while 
other inbred strains are rarely affected(97, 98). By three weeks of age, 1-10% of 129 
males have formed a TGCT, either a teratoma or a teratocarcinoma. These TGCTs are 
similar to those that form in newborn humans; they originate embryonically, and they 
lack CIS cells. Using these 129 mice, experiments grafting E12.5 and E13.5 gonads to 
adult testes showed that while 82% of E12.5 gonad grafts formed teratomas, only 8% of 
E13.5 gonads formed teratomas, indicating that PGCs could be the cell of origin of 
these tumors. Follow up experiments grafted precursor gonads (where the PGCs 
migrate to) to adult testes and found they also result in formation of teratomas. However 
if the genital ridge grafts are from KitlSl/Sl mice, which are germ cell deficient, few tumors 
form, supporting the conclusion that the PGCs are the teratoma cell of origin. 
 Further research into the nature of teratoma formation in the 129 mice has led to 
the discovery of several modifier genes including Pten, Trp53, Apobec1, Kitl, and Dnd1, 
the strongest of these being Dnd1. A C to T transition in the Dnd1 ORF (Dnd1Ter), which 
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introduces a premature stop codon in amino acid 178 and 190 in protein isoforms 
DND1-α and DND1-β respectively(99), spontaneously arose in the 129 mice. 
Homozygous Dnd1 mutants form teratomas in 94% of testes, while heterozygotes form 
teratomas in 17% of testes(100). Dnd1Ter/Ter are infertile on all genetic backgrounds 
tested, with roughly ten PGCs at E11.5(101), but result in teratomas only on the 129 
background(102, 103). 
 
Spermatocytic Seminomas: Canine seminoma 
 Canines develop TGCTs at a relatively high rate, about ten times higher than 
TGCT incidence in humans(104). These have been characterized as seminoma tumors 
based on their histology of a single cell type. Upon closer examination of these tumors 
in parallel with human spermatocytic seminomas, it was discovered that the canine 
seminomas are diploid, similar to human spermatocytic seminoma, and unlike the 
aneuploidy in human seminoma. This led Looijenga et. al. to conclude that canine 
seminomas are a model for human spermatocytic seminoma(104).  
 
Seminomas: Mouse GDNF-overexpression seminomas 
 GDNF is produced and secreted by the Sertoli cells, and acts by binding to its 
receptor complex on the surface of the germ cell. Gdnf is known to be required for SSC 
maintenance in mice. Mice overexpressing Gdnf in the testis form seminomatous 
tumors in their old age. These tumors histologically resemble the seminoma cells in 
humans, express alkaline phosphatase and are aneuploid, similar to human 
seminomas(105). However, these tumors did not show the characteristic precursor cells 
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of human seminomas, the CIS cells, prior to tumor formation. In addition, these tumors 
were benign, never metastasizing, also unlike human seminomas. Finally, no 
expression or imprinting analysis was done on these tumors, leaving open the question 
of their similarity to human seminoma. To date, there is no accepted animal model of 
human seminoma. 
 
Conclusions 
 
 The following chapters of this thesis discuss the roles of Stra8, a target gene of 
RA, during spermatogenesis. I will suggest that Stra8 acts in two roles during 
spermatogenesis, in the transition from Aal to A1 spermatogonia and in meiotic initiation. 
These data have led us to surmise a model whereby RA inducing Stra8 expression 
regulates these two transitions such that they occur simultaneously in the testis. This 
model leads to speculations about RA control over the seminiferous cycle.  
 In addition, I will discuss the role of Stra8 in testicular germ cell tumors. I will 
show data from Stra8-deficient mice on different genetic backgrounds that implicates 
Stra8 as a tumor suppressor gene in seminoma tumors in mice. Furthermore I will argue 
that the seminoma tumors that form in Stra8-deficient mice are a model for human 
seminomas. Evidence from 129Sv/S4Jae Stra8-deficient testes has led us to conclude 
that Stra8 is required for testicular teratoma tumors to form in the 129 genetic 
background mice, indicating an oncogenic role for Stra8 in teratoma formation.  
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 Chapter 2 
 
 
Stra8 and its inducer, retinoic acid, regulate 
meiotic initiation in both spermatogenesis and 
oogenesis in mice 
 
 
 
 
 
Published as Anderson, E., Baltus, A., Roepers-Gajadien, H., Hassold,T., de Rooij, D. 
van Pelt, A., and Page, D. Proc Natl Acad Sci U S A 105(39):14976-14980. 
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Abstract 
 
In eukaryotes, diploid cells give rise to haploid cells via meiosis, a program of two cell 
divisions preceded by one round of DNA replication.  While key molecular components 
of the meiotic apparatus are highly conserved among eukaryotes, the mechanisms 
responsible for initiating the meiotic program have diverged substantially among 
eukaryotes.  This raises a related question in animals with two distinct sexes:  Within a 
given species, are similar or different mechanisms of meiotic initiation employed in the 
male and female germ lines?  In mammals, this question is underscored by dramatic 
differences in the timing of meiotic initiation in males and females.  Stra8 is a vertebrate-
specific, cytoplasmic factor expressed by germ cells in response to retinoic acid.  We 
previously demonstrated that Stra8 gene function is required for meiotic initiation in 
mouse embryonic ovaries.  Here we report that, on an inbred C57BL/6 genetic 
background, the same factor is also required for meiotic initiation in germ cells of 
juvenile mouse testes.  In juvenile C57BL/6 males lacking Stra8 gene function, the early 
mitotic development of germ cells appears to be undisturbed.  However, these cells 
then fail to undergo the morphological changes that define meiotic prophase, and they 
do not display the molecular hallmarks of meiotic chromosome cohesion, synapsis and 
recombination.  We conclude that, in mice, Stra8 regulates meiotic initiation in both 
spermatogenesis and oogenesis.  Taken together with previous observations, our 
present findings indicate that, in both the male and female germlines, meiosis is initiated 
through retinoic acid induction of Stra8. 
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Introduction 
In mammals and other animals, both male and female germ cells undergo meiosis, a 
program of two cell divisions preceded by one round of DNA replication, resulting in 
halving of the chromosome number.  Many structural and enzymatic components of the 
mammalian meiotic apparatus are shared between males and females, and several of 
these components are conserved across the breadth of the eukaryotic world (106, 107).  
The mechanical elements of meiosis are remarkably conserved between the sexes and 
among species. 
The same cannot be said for the regulatory pathways that govern the transition of 
cells from mitosis to meiosis.  These pathways have been studied intensively in the 
budding yeast Saccharomyces cerevisiae and in the fission yeast 
Schizosaccharomyces pombe (108).  In these two species, the molecular mechanisms 
regulating meiotic initiation appear to share no components, and these initiation 
pathways do not appear to be conserved in multicellular organisms. 
In mammals, moreover, the timing and regulation of meiosis differ dramatically 
between the sexes (109, 110).  For example, all meioses in mammalian females initiate 
during a brief window in embryonic development, while meiotic initiation in males is first 
observed at puberty and then recurs repeatedly and continuously throughout adulthood.  
Do these sexual differences in timing reflect distinct mechanisms of meiotic initiation in 
females and males? 
An opportunity to explore this question experimentally arises from recent studies 
of Stra8 (Stimulated by retinoic acid gene 8), a vertebrate-specific gene that encodes a 
cytoplasmic protein and whose expression is induced by retinoic acid (30, 56, 62, 111-
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113).  Our laboratory previously reported that, in female mice, Stra8 is expressed in 
embryonic ovarian germ cells shortly before they enter meiotic prophase (114).  We 
further demonstrated that, in female embryonic germ cells, initiation of the meiotic 
program depends on Stra8 function.  Stra8 plays no role in the mitotic phases of 
embryonic germ cell development, but in females it is required for premeiotic DNA 
replication and the subsequent events of meiotic prophase, including chromosome 
condensation, cohesion, synapsis, and recombination (58).  These findings established 
that Stra8 is a regulator of meiotic initiation in females. 
In the present study, we address whether Stra8 serves an analogous function in 
males.  In male mice, Stra8 is expressed postnatally, in the mitotically active cells of the 
spermatogenic lineage (spermatogonia) and their immediate descendants (preleptotene 
spermatocytes), the most advanced cell type prior to meiotic prophase (56, 62, 115).  
We previously reported that male mice lacking Stra8 function produced no sperm; most 
spermatogenic cells underwent apoptosis at a developmental stage when they normally 
would have progressed through meiotic prophase (58).  While attempting to refine these 
preliminary observations, we detected variability in the spermatogenic phenotypes of 
Stra8-deficient males.  Suspecting that this confounding phenotypic variability might 
derive from genetic (strain background) variation unlinked to the Stra8 locus, we 
extensively backcrossed the Stra8 mutation onto an inbred strain.  Having neutralized 
unlinked genetic modifiers, we then proceeded to explore experimentally whether Stra8 
is required for meiotic initiation in male mice. 
 
Results 
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 Backcrossing to C57BL/6 in Response to Inconsistent Spermatogenic Defects in 
Stra8-Deficient Males of Mixed Genetic Background.  Our laboratory previously 
generated the Stra8 mutant allele (58) by homologous recombination in v6.5 embryonic 
stem (ES) cells, which had been derived from an F1 hybrid (C57BL/6 x 129) embryo 
(116).  Thus, our earlier studies of Stra8 function were conducted on animals of mixed 
rather than inbred genetic backgrounds (58).  All mutant animals were infertile, with no 
evidence of mature sperm.  Nonetheless, as we continued to characterize Stra8-
deficient testes using histological and immunocytochemical methods, we observed that 
meiotic progression and spermatocyte survival varied considerably between and within 
animals of the same Stra8 genotype.  While these phenotypes are potentially of interest, 
the mixed genetic backgrounds on which they had been observed would be difficult to 
reproduce.  Accordingly, we decided to forego further characterization of the Stra8-
deficient testicular phenotype until we had backcrossed the mutant allele onto an inbred 
strain background, in this case C57BL/6. 
 All experiments reported here were conducted on mice backcrossed for at least 
15 generations, when >99.9% of the genome is expected to be of C57BL/6 origin.  As 
previously reported for Stra8-deficient mice on a mixed genetic background (58), Stra8-
deficient C57BL/6 males and females were infertile, and we detected no phenotypic 
abnormalities apart from the gonads in either sex.  We observed no gonadal or 
extragonadal abnormalities in Stra8-heterozygous C57BL/6 animals of either sex, again 
consistent with our observations on a mixed genetic background (58). 
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Absence of Leptotene, Zygotene, or Pachytene Cells in Testes of Stra8-Deficient 
C57BL/6 Males.  Spermatogenesis in mice is a lengthy (>35 day), multifaceted process 
by which diploid spermatogonial stem cells give rise to haploid spermatozoa.  
Spermatogenesis involves two meiotic divisions, which modify the nucleus and its 
chromosomes, and also an elaborate program of cellular differentiation.  This 
differentiation program includes dramatic changes in cellular morphology and function, 
including postmeiotic acquisition of the ability to swim.  Many distinct steps in cellular 
differentiation, and in meiotic progression, have been defined through microscopic 
studies of spermatogenesis in mice (115).  In the testis of an adult mouse, one finds 
spermatogenic cells at all stages of differentiation and meiotic progression.  To study 
meiotic initiation in a simpler and more nearly synchronous setting, we focused instead 
on the testes of juvenile males at 10 to 21 days after birth, when the first and second 
cohorts of spermatogenic cells normally enter prophase of the first meiotic division.  
This allowed us to assay male meiotic initiation in the absence of later meiotic and post-
meiotic cells. 
 We began by comparing the histologies of wildtype and Stra8-deficient testes at 
10 and 15 days after birth.  We paid particular attention to the spermatogenic cells’ 
chromatin, whose changing microscopic appearance serves to define the stages of 
meiotic prophase.  As expected, by p10 (10 days of age) in wildtype C57BL/6 males, 
pioneer cohorts of spermatogenic cells have initiated meiosis and progressed to 
leptotene, the first stage of meiotic prophase (see red arrows in Fig. 1).  By p15 in 
wildtype C57BL/6 males, the most advanced cohorts have transited zygotene and 
progressed to pachytene of meiotic prophase (see green arrows in Fig. 1).  By contrast,  
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Figure 1. Photomicrographs of hematoxylin-stained sections from
wildtype and Stra8-deficient testes at p10 or p15 (10 or 15 days 
after birth, respectively). Black arrows indicate representative 
preleptotene spermatocytes. Red arrows, leptotene spermatocytes. 
Green arrows, pachytene spermatocytes. Arrowheads, apoptotic
cels.
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in Stra8-deficient C57BL/6 testes, we found no leptotene, zygotene, or pachytene 
spermatocytes at either p10 or p15 despite extensive searching.  Instead, the most 
advanced spermatogenic cells that we observed in Stra8-deficient animals were at the 
preleptotene stage – the last microscopically defined stage prior to meiotic prophase 
(see black arrows in Fig. 1).  As expected, preleptotene cells are also present in 
wildtype testes (Fig. 1).  These findings suggested that, in C57BL/6 males, Stra8 
function is required for spermatogenic cells to transition from preleptotene to leptotene, 
and thus to enter meiotic prophase.  We also note that apoptotic cells were observed in 
some Stra8-deficient testicular tubules but were rarely seen in wildtype testes (Fig. 1).  
In summary, histological examination suggested that germ cell development in juvenile 
Stra8-deficient C57BL/6 males proceeded normally to the preleptotene stage, but 
stalled there without progressing into meiotic prophase. 
 To examine this working hypothesis, we then tested juvenile Stra8-deficient 
testes for key molecular hallmarks of meiotic prophase. 
 
Absence of Meiotic Recombination in Testes of Stra8-Deficient C57BL/6 Males.  
Recombination between homologous chromosomes occurs during prophase of the first 
meiotic division.  If Stra8 is required for preleptotene cells to progress into meiotic 
prophase, as indicated by our histological studies (Fig. 1), then spermatogenic cells in 
Stra8-deficient testes should not engage in meiotic recombination.  We first tested this 
prediction by assaying whether Stra8-deficient testicular germ cells form DNA double-
strand breaks (DSBs), which initiate meiotic recombination.  When DNA DSBs are 
formed, cells respond by phosphorylating H2AX, an isoform of histone H2A, to generate 
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γ-H2AX (117).  We tested for γ-H2AX by immunostaining sections from p10 wildtype 
and Stra8-deficient testes.  As expected, γ-H2AX staining demonstrated the presence of 
DNA DSBs in many cells of wildtype testes (Fig. 2).  By contrast, γ-H2AX staining is 
absent in Stra8-deficient testes, indicating that DNA DSBs have not formed (Fig. 2). 
 To further examine their capacity for meiotic recombination, we assayed whether 
spermatogenic cells in Stra8-deficient testes express Spo11, encoding a topoisomerase 
required to form meiotic DSBs (118, 119), and Dmc1, which encodes a recombinase 
functioning in meiotic DSB repair (120, 121).   We measured mRNA expression of 
Spo11 and Dmc1 in control and Stra8-deficient testes at p10 and p15 using quantitative 
RT-PCR (Fig. 3).  We found that mRNA expression of both genes was dramatically 
reduced in Stra8-deficient testes at both time points.  Taken together, our γ-H2AX, 
Spo11, and Dmc1 findings provide strong evidence that spermatogenic cells in Stra8-
deficient testes do not form or repair meiotic DSBs, and thus do not undertake meiotic 
recombination. 
 
Absence of Meiotic Cohesion and Synapsis in Testes of Stra8-Deficient C57BL/6 
Males.  Like meiotic recombination, meiotic chromosome cohesion and synapsis are 
molecularly defined processes that underpin proper chromosome segregation, and both 
are hallmark features of meiotic prophase.  If Stra8 is required for preleptotene cells to 
enter meiotic prophase, then chromosomal cohesion and synapsis should not occur in 
spermatogenic cells of Stra8-deficient testes.  To test this prediction, we immunostained 
cell spreads from wildtype and Stra8-deficient testes at p15 using antibodies against 
either REC8, a meiosis-specific cohesin (122-128), or SYCP3, a synaptonemal complex  
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protein (129).  We simultaneously immunostained for GCNA, a germ-cell specific 
marker (130), to distinguish between spermatogenic and somatic cells in these 
populations of dispersed cells.  As expected, SYCP3 and REC8 decorated the lengths 
of the chromosomes in most wildtype spermatogenic cells at p15, demonstrating the 
presence, respectively, of synaptonemal and meiotic cohesin complexes (Fig. 4).  By 
contrast, in Stra8-deficient spermatogenic cells, the SYCP3 and REC8 proteins, though 
present, did not appear to be loaded onto chromosomes (Fig. 4), but instead were 
localized in patterns reminiscent of those previously reported in premeiotic germ cells, 
including germ cells of Stra8-deficient embryonic ovaries (58, 131).  We concluded that, 
in spermatogenic cells of juvenile C57BL/6 males, Stra8 function is required for meiotic 
cohesion and synapsis to occur. 
 
Abundant DNA Replication in Preleptotene Cells of Stra8-Deficient C57BL/6 
Males.  Taken together, our results lead us to conclude that in germ cells of juvenile 
C57BL/6 males, Stra8 is required for both the histological and molecular manifestations 
of meiotic prophase, including chromosomal cohesion, synaptonemal complex 
formation, and recombination.  Thus, in the absence of Stra8 function, spermatogenic 
cells in juvenile C57BL/6 males progress to the preleptotene stage but do not enter 
meiotic prophase.  In wildtype testes, it is thought that preleptotene cells replicate their 
DNA immediately before they advance into meiotic prophase (115).  The question then 
arises whether Stra8-deficient preleptotene cells also replicate their DNA. 
 We explored this question at p21, when, in wildtype testes, a second round of 
preleptotene cells form and replicate their DNA.  At that time, the neighboring somatic  
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(Sertoli) cells have stopped dividing, effectively eliminating the noise that these somatic 
cells might otherwise contribute to an analysis of germ cell replication (132).  We 
injected bromodeoxyuridine (BrdU) into wildtype and Stra8-deficient male mice and two 
hours later harvested the testes.  We immunostained testicular sections to detect 
incorporation of BrdU into newly replicated DNA in preleptotene and other 
spermatogenic cell types.  Within these sections, we identified preleptotene and other 
spermatogenic cells by their location, nuclear size and chromatin pattern (115).  In both 
wildtype and Stra8-deficient testes, we found many BrdU-positive preleptotene cells, 
indicating that DNA replication had occurred (Fig. 5).  These results demonstrate that 
Stra8 is not required for preleptotene cells to replicate their DNA. 
 
Discussion 
Here we have demonstrated that, on a highly inbred C57BL/6 genetic background, 
Stra8 is required for male meiotic initiation -- for preleptotene cells in juvenile mouse 
testes to transition into meiotic prophase.  Specifically, we have found that Stra8 is 
required for spermatogenic cells to undergo the morphological changes that define 
meiotic prophase, and for these cells to exhibit the molecular hallmarks of meiotic 
chromosome cohesion, synapsis and recombination.  However, Stra8 is not required for 
preleptotene cells of juvenile testes to undergo DNA replication.  We will now discuss 
the implications of these findings for our understanding of meiotic initiation in mice and 
other multicellular organisms. 
 Although many genes in addition to Stra8 have been shown to be required for 
meiosis in male mice, these genes function during or after meiotic prophase and are not  
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needed for preleptotene cells to transition into meiotic prophase.  For example, 
spermatogenic cells deficient in either Rec8, Smc1b, Sycp3, Spo11, or Dmc1 readily 
progress into meiotic prophase (43, 118-129).  To our knowledge, Stra8 displays the 
earliest meiotic phenotype among characterized mutants affecting the male mouse 
germline.  Remarkably, all of these statements also hold true for Stra8’s function in the 
female germline (58).  Thus, Stra8 appears to function upstream of all other known 
meiotic mutants in both spermatogenesis and oogenesis, yet it is not required in 
embryos of either sex, or in juvenile males, for the early mitotic development of the 
germline. 
 Our present findings, together with previous work from our and other 
laboratories, lead us to hypothesize a common molecular pathway for meiotic initiation 
in the mammalian male and female germlines in vivo.  Specifically, we postulate that, in 
both sexes, retinoic acid (RA) produced in somatic cells acts directly upon germ cells to 
induce expression of Stra8, which in turn is required for initiation of the meiotic program.  
There is now much data in vivo and in vitro, in one or both sexes, to support this model.  
First, the model rests on the evidence, presented here and in our previous study (58), 
that Stra8 function is required, in vivo, for meiotic initiation in the male and female 
germlines.  Second, there is a wealth of evidence that in vivo expression of Stra8 is 
germline-specific in both sexes, and that Stra8 expression in germ cells of embryonic 
ovaries and juvenile and adult testes is induced by, and requires, RA signaling (56, 62, 
111-114).  Finally, in vitro studies of isolated spermatogenic cells suggest that RA acts 
directly on germ cells to induce Stra8 expression (30).  Combined with previous reports, 
our present findings suggest that the meiotic initiation pathway in which Stra8 and its 
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inducer, RA, figure so prominently is shared between the male and female germlines in 
vivo.  This male-female commonality in the regulation of meiotic initiation provides a 
counterpoint to profound sexual dimorphisms in regulatory checkpoints during meiotic 
prophase (109, 110). 
 This model and our findings also raise fundamental questions for future study.  
First, it remains to be determined whether mammalian regulators of meiotic initiation 
aside from Stra8 and RA are sex-specific or are shared between the sexes.  Second, 
apart from mammals, it will be of great interest to learn whether spermatogenesis and 
oogenesis within a given species employ common regulators of meiotic initiation.  This 
is the case in the nematode C. elegans, where gld-1 and gld-2 appear to play similar 
roles in regulating meiotic initiation in spermatogenesis and oogenesis (133, 134).  
Finally, it is intriguing that Stra8-deficient preleptotene cells replicate their DNA but fail 
to enter meiotic prophase.  One possible explanation is that these cells, despite having 
taken on the morphological appearance of preleptotene spermatocytes, retain the 
proliferative character of spermatogonia.  This would account for the apparent failure of 
REC8 loading in spermatogenic cells of Stra8-deficient testes (Fig. 4), as this loading is 
a hallmark of premeiotic but not mitotic DNA replication (124).  By this model, Stra8 
regulates meiotic initiation upstream of premeiotic DNA replication in both sexes (58).  
This model also aligns with evidence from C. elegans, where failure to initiate meiosis 
may result in continued mitotic proliferation of germ cells (133, 134).  Experiments to 
explore these questions can now be envisioned. 
 
Materials and Methods 
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 Mice.  Stra8 heterozygous mice (58) were crossed to C57BL/6NtacfBR mice (Taconic 
Farms Inc., Germantown, NY).  All experiments were carried out on mice backcrossed 
to C57BL/6NtacfBR between 15 and 17 generations, when greater than 99.9% of the 
genome is expected to be of C57BL/6NtacfBR origin; all Y chromosomes and 
mitochondria are of C57BL/6NtacfBR origin.  Stra8-deficient males were generated by 
mating heterozygotes.  Stra8 genotypes were assayed by PCR as previously described 
(58).  All experiments involving mice were approved by the Committee on Animal Care 
at the Massachusetts Institute of Technology. 
 
Histology.  Testes were fixed overnight in Bouin’s solution, embedded in paraffin, 
sectioned and stained with hematoxylin. 
 
γ–H2AX Immunohistochemistry.  Testes were fixed overnight in Bouin’s solution, 
embedded in paraffin and sectioned.  Slides were de-waxed, rehydrated and 
microwaved in 10 mM Sodium Citrate buffer, pH 6.0 for 10 min.  Slides were then 
treated with 2% donkey serum for 30 min and washed with phosphate-buffered saline 
(PBS).  Slides were then incubated for 60 min in a 1:100 dilution of rabbit polyclonal 
anti-γ–H2AX (Upstate Biotech).  Slides were washed with PBS and incubated for 60 min 
at room temperature with donkey anti-rabbit secondary antibody, conjugated with Texas 
Red (Jackson ImmunoReseach Laboratories), at 1:200 dilution. 
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Quantitative RT-PCR.  Testes were stripped of the tunica albuginea, placed in Trizol 
(Invitrogen) and stored at -20°C.  Total RNAs were prepared according to the 
manufacturer’s protocol.  Total RNAs were then DNase treated using DNA Free Turbo 
(Ambion).  One ug of total RNA was reverse transcribed using a RETROScript kit 
(Ambion).  Quantitative PCR was performed using SYBR Green Core PCR Reagents 
(Applied Biosystems) on an ABI9700 Fast Real-time PCR machine (Applied 
Biosystems).  Results were analyzed using the delta-delta Ct method using Hprt 
(hypoxanthine-guanine phosphoribosyltransferase) as a normalization control. 
RT-PCR primer sequences were as follows: 
Spo11: 5' CGTGGCCTCTAGTTCTGAGGT 3' and 5' 
GCTCGATCTGTTGTCTATTGTGA 3' 
Dmc1: 5' CCCTCTGTGTGACAGCTCAAC 3' and 5' GGTCAGCAATGTCCCGAAG 3' 
Hprt: 5' TCAGTCAACGGGGGACATAAA 3' and 5' GGGGCTGTACTGCTTAACCAG 3' 
 
SYCP3 and REC8 Immunocytochemistry.  Testes were dissected from p15 male 
mice.  To obtain single cells, tubules were teased apart with forceps, minced, and 
pipetted repeatedly in PBS.  Cells were pelletted and resuspended once in PBS and 
twice in hypotonic solution (0.5% sodium chloride in H2O).  Cell suspensions were then 
placed on poly-L-lysine-coated slides and kept in a humid chamber at room temperature 
(22°C) for 60 min.  The slides were then fixed in 2% paraformaldehyde and 0.03% SDS 
for 15 min at 4°C, washed three times in 0.4% Photoflo (Kodak) for 1 min and air dried.  
These slides were stored at –80°C before use. 
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Prior to fluorescence immunostaining, slides were brought to room temperature, 
washed twice in PBS and treated with blocking buffer (10% donkey serum, 10% goat 
serum, 0.05% Triton X-100 in PBS).  Slides were then incubated with anti-GCNA IgM 
(courtesy of G. Enders, undiluted supernatant) and a 1:1000 dilution of rabbit anti-
SYCP3 IgG or anti-REC8 IgG (courtesy of C. Heyting) overnight at 4°C.  Slides were 
then washed with PBS and incubated for 60 min at room temperature with donkey anti-
rabbit secondary antibody, conjugated with either Texas Red or fluorescein 
isothiocyanate (Jackson ImmunoReseach Laboratories), at 1:200 dilution. 
 
5-Bromo-2-deoxyuridine (BrdU) Incorporation.  21-day-old male mice were injected 
intraperitoneally with 10µl/gram body weight of 20g/L BrdU in PBS.  The mice were 
euthanized 2 h later.  Testes were fixed overnight in Bouin’s solution, embedded in 
paraffin, and sectioned.  Slides were de-waxed, rehydrated, and pretreated with 1% 
periodic acid at 60°C for 30 min.  Slides were then incubated in 5% bovine serum 
albumin, followed by a 30 min incubation with mouse anti-BrdU sera (BD Bioscience) at 
a dilution of 1:80.  Slides were then washed with PBS and incubated with anti-mouse 
secondary antibody conjugated with horseradish peroxidase (ImmunoVision 
Technologies, Co.).  Peroxidase activity was visualized using 3,3-diaminobenzidine-
tetrahydrochloride (Sigma) as substrate.  Sections were counterstained with 
hematoxylin. 
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Abstract 
 Spermatogenesis is a complex forty day process in mice, which includes three 
major processes: stem cell renewal and differentiation and expansion by 
spermatogonial progenitor cells by mitotic division; halving of chromosomal number in 
the spermatocyte progenitor cells by meiotic division; and the unique differentiation of 
these haploid spermatid progenitor cells. The expansion of spermatogonial progenitor 
cells and the entry into meiotic division are known to require retinoic acid (RA) signaling, 
but only the RA target that exerts this function in spermatocyte progenitor cells is 
known. The decision to enter the meiotic process is known to require Stra8, a germ cell 
specific, RA target gene. The RA targets that exert its function in spermatogonial 
progenitor cells is unknown.  
Here we report that at one year of age, Stra8-deficient mice form testicular 
tumors composed of cells with A spermatogonial morphology and expressing markers 
of A spermatogonia at the RNA and protein levels. These tumors do not express meiotic 
markers, or markers specific to embryonic male germ cells. We show that STRA8 is 
expressed in a subset of spermatogonia paralleling the beginning of spermatogonial 
differentiation. In Stra8-deficient testes on a C57BL/6NtacfBR genetic background, 
before the onset of tumor formation, we observe abnormal accumulations of LIN28+ 
spermatogonia, and an increased number of LIN28+ spermatogonia. In contrast, 
spermatogonial accumulations are absent from Stra8-deficient testes on a 129S4/SvJae 
genetic background. The Stra8-deficient testes on a C57BL/6NtacfBR genetic 
background have a spermatogonial tumor incidence of 85% while on 129S4/SvJae we 
observe spermatogonial tumors in only 6% of animals, consistent with the absence of 
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spermatogonial accumulations on this genetic background. These findings suggest that 
the accumulating spermatogonia are precursors to the testicular tumors. Ccnd2, a gene 
implicated in human testicular cancer is required for the formation of Stra8-deficient 
testicular tumors. These observations indicate a role for Stra8 in spermatogonial 
differentiation. 
 
Introduction 
In mammals, males are able to produce sperm from puberty through their entire 
adult life. This continuous production of sperm is achieved by the resident stem cell 
population in the testis, the spermatogonial stem cells (SSC). The SSC retain the ability 
to self-renew as well as to differentiate. The process by which a SSC differentiates into 
a sperm cell, spermatogenesis, is a complex, highly regulated process consisting of 
three major processes: mitotic expansion of progenitor cells; meiotic division to form 
haploid cells; and cellular differentiation of sperm. Spermatogenesis begins with the 
SSC differentiating into a mitotic progenitor cell. The mitotic progenitor cells are 
generally termed spermatogonia. The early mitotic progenitors are defined as 
“undifferentiated” and include the SSC. At regular intervals the undifferentiated 
spermatogonia form the first of six “differentiating” spermatogonia, the A1 
spermatogonia. The transition from undifferentiated to differentiating spermatogonia is 
distinct from all other spermatogonial transitions in that it occurs during a G1 phase and 
is not a cell division. The A1 spermatogonia then undergo a mitotic division that is the 
start of a series of six mitotic divisions of differentiating spermatogonia that culminates 
in the formation of preleptotene spermatocytes. The preleptotene spermatocyte is the 
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germ cell that enters the meiotic process after completing the final germ cell DNA 
replication during spermatogenesis. At the completion of meiosis, haploid germ cells, 
termed spermatids, are formed. These spermatids then undergo dramatic changes in 
cellular morphology to become sperm(115). 
Vitamin A is required for fertility.  Studies using vitamin A-deficient (VAD) rodents 
have shown a requirement for vitamin A at the transition from undifferentiated 
spermatogonia to differentiating A1 spermatogonia(29, 46). In addition, the transition 
from preleptotene to leptotene spermatocytes (meiotic initiation) is also vitamin A 
dependent(46, 135). These blocks can both be rescued by injection of either retinol 
(vitamin A) or retinoic acid (RA, an oxidized form of vitamin A), suggesting that RA is the 
factor governing these transitions(136, 137). The actions of vitamin A in the testis are 
governed by its transport, metabolism, degradation of retinoids, and activation of its 
nuclear receptors. Dietary vitamin A (retinol) is stored in the liver and then transported 
to target tissues like the testis, where intracellular binding proteins and retinoid 
metabolism enzymes regulate the production and degradation of RA. Retinoic acid, 
thought to be the mediator of vitamin A function in the testis, binds to two kinds of 
intracellular receptors termed RA receptors (RARs) and retinoid X receptors (RXRs). 
These receptors regulate gene expression as homo- and heterodimers by binding to 
specific elements in the promoter regions of target genes. One known germ cell target 
gene is “stimulated by retinoic acid 8” (Stra8)(138).   
A screen for RA responsive genes discovered Stra8. In this screen F19 
carcinoma cells were treated with RA, and then the induced genes were cloned and 
characterized. This study found STRA8 to be exclusively expressed in male premeiotic 
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cells(56). Further characterization of the expression of Stra8 revealed this was incorrect 
and that both male and female premeiotic cells express Stra8(114). Deletion of Stra8 in 
both male and female mice has shown a requirement for Stra8 in meiotic initiation in 
both sexes, consistent with a role for RA at this transition(58, 139, 140). A detailed 
characterization of STRA8 expression in the postnatal testis has shown STRA8 is 
expressed in the spermatogonial population several mitotic divisions before it’s 
expression in meiotic cells(30, 62). Additionally, in the VAD model, after RA restoration, 
Stra8 expression is greatly induced(111). This finding of STRA8 expression in 
differentiating spermatogonia, beginning six mitotic divisions before meiosis, begs the 
question of whether Stra8 plays a role in spermatogonial differentiation. The work 
described herein describes the function of Stra8 in spermatogonial cells.  
 
Results 
Stra8-deficient testes form testicular tumors composed of type A spermatogonia. 
During the course of an aging study on Stra8-deficient C57BL/6NtacfBR mice, 
we observed a striking phenotypic difference in the testes of one-year old mice. 
Wildtype testes at one year of age range in weight from 100mg-200mg (Fig 1a). In 
contrast, we found that Stra8-deficient testes weighed from 20mg-4000mg (Fig1a). 
Compared to the consistent histology of a wildtype testis at one year where many germ 
cell types are present (Fig 1b), the histology in Stra8-deficient testes at one year differs 
greatly. The majority of Stra8-deficient testes at one year (85%) contain at least one 
tubule where the cross section of the tubule is filled with proliferating type A 
spermatogonia that have broken out of the basal compartment. We classify this as a  
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testicular tumor. Within these Stra8-deficient testicular tumors are two sub-groups, 
those where the entire testis is composed of proliferating type A spermatogonial cells, 
along with the remnants of seminiferous tubules and the interstitium (Fig1e,f) and those 
where most tubules either contain germ cells developing up to preleptotene 
spermatocyte stage or are devoid of germ cells and rare tubules where the cross 
section of the tubule is filled with proliferating type A spermatogonia that have broken 
out of the basal compartment (Fig1d). The remaining 15% of Stra8-deficient testes at 
one year weigh 50mg or less and contain tubules that either contain germ cells 
developing up to preleptotene spermatocyte stage or are devoid of germ cells (Fig1c). 
 To confirm our histological observations that Stra8-deficient testicular tumors are 
composed of type A spermatogonia, we examined the gene expression of the tumors. 
Using quantitative Real Time PCR (qRT-PCR) to compare average tumor expression to 
average wildtype adult testis expression, and immunohistochemistry, the germ cell 
composition of the Stra8-deficient tumors was confirmed by a higher relative expression 
of the germ cell specific gene Dazl(141, 142) (Fig2a,c), expression of MVH(143, 144) 
(Fig2c), and the relative absence of somatic specific genes; Sertoli cells – Clu(145), 
Leydig cells – Cyp17a1(146), Lh-r(146) (Fig2a).   
We next explored meiotic gene expression in the Stra8-deficient tumors. Based 
on Stra8’s known requirement for meiotic initiation(58, 139, 140), we considered the 
possibility that the block in meiotic initiation could cause the Stra8-deficient preleptotene 
spermatocytes to continue to divide by mitosis, as shown for Stra8-deficient 
preleptotene spermatocytes on a mixed genetic background(140). However, the tumors 
were found to have relatively no expression of meiotic markers (Rec8(42), Scp1(147),  
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Scp3(147), Spo11(148), Dmc1(149)) compared to the expression found in the adult 
wildtype testis, indicating that the tumor does not originate from an aberrant mitotically 
dividing spermatocyte cell (Fig2a).  
We explored the possibility that the Stra8-deficient tumors originate from an 
embryonic germ cell by testing the tumors for expression of Nanog and Dppa3, genes 
that are expressed by male germ cells in the embryonic gonad but not after birth in 
mice(150). Compared to the expression in E13.5 male gonads, the expression of both 
Dppa3 and Nanog in the Stra8-deficient tumors was absent, similar to the expression 
levels detected in the adult wildtype testes (Fig2b), indicating that the tumors do not 
arise from an embryonic germ cell. This is consistent with the absence of Stra8 
expression in male embryonic germ cells(114).  
We then tested the tumors for type A spermatogonial expression as the 
morphology of the Stra8-deficient tumors is of type A spermatogonia, and the Stra8-
deficient tumors do not appear to have a meiotic nor an embryonic germ cell origin. 
Type A spermatogonia include both undifferentiated spermatogonia and differentiating A 
spermatogonia. To distinguish which of these A spermatogonial types compose the 
tumor, we assayed the expression of undifferentiated spermatogonial markers Utf1(26), 
Gfrα1(151, 152), Nanos2(153, 154), Neurog3/Ngn3(155), Pou5f1/Oct4 (23), and 
Zbtb16/Plzf (5, 6), and differentiating spermatogonial markers Sohlh2 (40, 156), 
Ccnd2(157) and Kit (158) (Fig2a). We found that the expression levels of both 
undifferentiated and differentiating spermatogonial markers were higher in Stra8-
deficient tumors than in wildtype testes, indicating expression of both undifferentiated 
and differentiating A spermatogonia. We confirmed the expression of undifferentiated 
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spermatogonia in the Stra8-deficient tumors using a marker of undifferentiated 
spermatogonia PLZF(5, 6). We found that a subset of the Stra8-deficient tumor cells 
express PLZF (Fig2c), indicating that some of the Stra8-deficient tumors cells are 
undifferentiated spermatogonia. This undifferentiated spermatogonial population could 
represent a cancer stem cell population in the tumor. We also confirmed some of the 
Stra8-deficient tumor cells are differentiating spermatogonia by assaying SOHLH2 
expression (Fig2c), a marker of differentiating spermatogonia (40, 156). 
 
STRA8 protein is expressed in undifferentiated spermatogonia transitioning to 
differentiating A spermatogonia and in all differentiating type A spermatogonia, 
but not in Intermediate or B spermatogonia. 
The type A spermatogonial nature of the Stra8-deficient tumors indicated a role 
for Stra8 function in spermatogonia. We examined STRA8 expression in spermatogonia 
in order to determine if this hypothesis was plausible. Consistent with previously 
published results(30, 62), STRA8 was found to be expressed in most, but not in all type 
A spermatogonia, but was not expressed in Intermediate or type B spermatogonia (Fig 
3a). This led us to ask whether undifferentiated A spermatogonia express STRA8. To 
investigate this, we looked for overlapping expression of STRA8 and a marker of 
undifferentiated A spermatogonia, PLZF(5, 6). Indeed, in the adult testis we found rare 
spermatogonial cells expressing both STRA8 and PLZF (Fig3b). In the testis, the SSC 
regularly give rise to differentiating progeny such that there is a cyclical nature of 
spermatogenesis characterized as the seminiferous cycle. In mice, this cycle is divided 
into 12 stages, where each stage is a cohort of different germ cell types found  
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developing together based on the regular formation of SSC differentiating progeny. The 
first appearance of differentiating A spermatogonia occurs in one such group of stages 
(VI-VIII). The double positive STRA8 and PLZF expressing spermatogonial cells were 
only found in these stages (VI-VIII), but not all PLZF positive cells were expressing 
STRA8 during these stages. This indicates that these double positive cells are actively 
transitioning from undifferentiated to differentiating A spermatogonia. To test this 
conclusion, we looked at the expression of STRA8 and PLZF in the postnatal day 3 (p3) 
testis where the first differentiating A spermatogonia are appearing. Compared to the 
relative number of germ cells making this transition in the adult testis, at p3 this 
transition is very frequent. We predicted that we should find an increased number of 
double positive cells if they were in fact the transitional cells. In support of this 
conclusion, STRA8 and PLZF double positive cells were common in the p3 testis (Fig 
3b).  
 
Clusters of type A spermatogonia accumulate in Stra8-deficient testes.  
 Intriguingly, in rare tubules in testes of one-month old Stra8 deficient mice 
clusters of type A spermatogonia were observed. Compared to the normal distribution of 
spermatogonia in wildtype testes (Fig 4a) and the majority of Stra8-deficient tubules 
where type A spermatogonia are spaciously distributed in a single layer along the outer 
rim of the tubules (Fig4b), we find clusters of type A spermatogonia distributed in a 
compacted way, characteristically showing multiple layers of spermatogonia (Fig 4c).   
As a result of the defect in meiotic initiation, Stra8-deficient tubule diameter is 
decreased relative to wildtype tubules as they have not expanded to contain meiotic and  
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post-meiotic germ cells. The observed A spermatogonia clusters could be a 
consequence of this decreased tubule size in the Stra8-deficient testes. To account for 
this possibility, we examined Dmc1-deficient testes, which have a meiotic prophase 
defect(120, 121) and the accompanying decreased tubule diameter, for A 
spermatogonia clusters.  We did not observe any A spermatogonia clusters in Dmc1-
deficient testes (Figure 5), indicating that the clusters observed in Stra8-deficient testes 
are not the result of reduced tubule size, but rather a specific effect of Stra8-deficiency. 
 
A spermatogonial clusters in Stra8-deficient testes are composed of 
undifferentiated spermatogonia. 
 We next asked what subtype of type A spermatogonia accumulate in Stra8-
deficient testes. We looked at a marker of undifferentiated spermatogonia, LIN28(24). 
We found that the A spermatogonia cluster cells in Stra8-deficient testes express LIN28 
(Fig4d-f), indicating that undifferentiated spermatogonia accumulate in the absence of 
Stra8 and result in undifferentiated A spermatogonia clusters. We also examined LIN28 
expression in p10 Stra8-deficient testes. Although we do not observe A spermatogonia 
clusters at this time point (data not shown), the number of LIN28+ spermatogonia at one 
month begs the question of whether the accumulation began earlier. We found an 
overall increased number of LIN28+ spermatogonia (5699 LIN28+ cells vs. 3282 LIN28+ 
cells) and an increased number of LIN28+ spermatogonia per tubule (10.10 LIN28+ 
cells/tubule vs. 4.74 LIN28+ cells/tubule) in Stra8-deficient testes at p10 compared to 
wildtype testes (Fig4g,h). This accumulation of LIN28+ spermatogonia indicates a defect  
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in spermatogonial differentiation, consistent with STRA8 expression beginning as 
undifferentiated spermatogonia differentiate. 
 
Stra8-deficient undifferentiated spermatogonial accumulation is a precursor to A 
spermatogonial tumor formation. 
We observe that all Stra8-deficient testes on a C57BL/6NtacfBR genetic 
background include tubules containing A spermatogonia clusters. In contrast, we found 
that Stra8-deficient testes on a 129Sv/S4Jae genetic background do not include any 
tubules containing A spermatogonia clusters (Fig3d, Figure 5). We do observe A 
spermatogonia clusters in Stra8-deficient testes on a mixed 
C57BL/6NtacfBR/129Sv/S4Jae genetic background, but this phenotype is not 
consistent between different Stra8-deficient testes (data not shown).  We find that the 
highest spermatogonial tumor incidence is consistent with the highest A spermatogonia 
cluster incidence, both on the C57BL/6NtacfBR genetic background (Table 1). 
Additionally, we find that the lowest spermatogonial tumor incidence is consistent with 
the lowest A spermatogonia cluster incidence both on the 129Sv/S4Jae genetic 
background (Table 1) and intermittent incidences of spermatogonial tumors and A 
spermatogonia clusters are observed on the mixed C57BL/6NtacfBR/129Sv/S4Jae 
genetic background (data not shown). This indicates that the A spermatogonia clusters 
are a precursor to the spermatogonial tumors. In support of the A spermatogonia 
clusters as precursors to the spermatogonial tumors, we observe that the A 
spermatogonia clusters in three-month old Stra8-deficient testes expand further along 
the length of the tubule than those in the one-month old Stra8-deficient testes, indicating  
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that these clusters continue to grow along the length of the tubule as the animal ages, 
eventually forming the Stra8-deficient spermatogonial tumors.  
We then tested Stra8-deficient spermatogonial tumors for LIN28 expression to 
see if these LIN28+ accumulated cells were precursors to the tumors. We found that 
similar to PLZF, some but not all of the Stra8-deficient spermatogonial tumor cells 
express LIN28. Combined with our previous results correlating A spermatogonia 
clusters with clusters of LIN28+ spermatogonia and with type A spermatogonial tumor 
formation, and the continuous growth of the A spermatogonia clusters as the animals 
age, these result indicates that these accumulated LIN28 expressing cells are the 
precursors to the Stra8-deficient spermatogonial tumors. 
 
Stra8-deficient spermatogonial tumors do not result from meiotic defect. 
The observed meiotic defect in Stra8-deficient testes could also be the cause of 
the spermatogonial tumors. We observe a meiotic defect in Stra8-deficient testes on all 
genetic background strains tested, C57BL/6NtacfBR(139), 129Sv/S4Jae (Figure 5), and 
mixed C57BL/6NtacfBR/129Sv/S4Jae(58, 140) genetic backgrounds. Despite a meiotic 
block in all of these genetic backgrounds, we observe a varying spermatogonial tumor 
incidence (Table 1). Whereas 85% of C57BL/6NtacfBR Stra8-deficient testes develop 
spermatogonial tumors, only 45% and 7% of mixed C57BL/6NtacfBR/129Sv/S4Jae and 
129Sv/S4Jae Stra8-deficient testes develop spermatogonial tumors, respectively.  This 
indicates that the spermatogonial tumors do not arise as a result of the meiotic defect 
but from the defect in spermatogonial differentiation. 
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Ccnd2 is required for Stra8-deficient testicular tumor formation. 
 During the expression analysis of Stra8-deficient spermatogonial tumors, it was 
discovered that cyclin D2 (Ccnd2) is highly expressed (Fig2a). Ccnd2 expression in the 
testis begins as undifferentiated A spermatogonia transition into the first differentiating A 
spermatogonia(157), which is consistent with the first expression of STRA8 (Fig3b), 
indicating that there could be a causal role to the expression of Ccnd2 in the Stra8-
deficient spermatogonial tumors. We found that the Stra8-deficient spermatogonial 
tumors express Ccnd2 specifically, as the expression of the other D type cyclins, Ccnd1 
and Ccnd3 (Fig6a) is relatively absent compared to adult wildtype testis expression. 
Ccnd2 is also known to be highly expressed in human seminomas(159), with 
expression in the precursor cells and the most invasive seminomas, and is thought to 
result from isochromosome formation of human 12p, a portion of the chromosome that 
contains the Ccnd2 gene. These 12p isochromosomes are formed in up to 80% of 
invasive seminomas, and those without 12p isochromosomes have gained additional 
12p sequences(72, 160). From these observations, we considered the possibility that 
Ccnd2 is required for Stra8-deficient tumor formation. To test this possibility, we crossed 
the Stra8 mice with the Ccnd2 mice in order to create Stra8, Ccnd2-deficient mice. We 
then assayed at one year the presence or absence of tumors in Stra8-deficient, Ccnd2-
deficient, and Stra8, Ccnd2-deficient testes. The Ccnd2-deficient mice were on a mixed 
genetic background composed of C57BL/6NtacfBR and 129S4/SvJae, so they were 
crossed with the Stra8-deficient mice also on this same mixed genetic background. We 
found that the Stra8-deficient testes had a tumor incidence of 24% (Fig6b,c) on this  
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mixed genetic background (C57BL/6NtacfBR/129S4/SvJae). Ccnd2-deficient testes 
have a normal histology (Fig6b) and do not form spermatogonial tumors, however 
homozygous mutant mice are reported to have a reduced sperm count despite 
remaining fertile(159). At one month and three months of age, the Stra8, Ccnd2-
deficient testes have histology similar to Stra8-deficient testes with germ cells 
developing only to the point of preleptotene spermatocytes (Figure 7). At one year of 
age in the Stra8, Ccnd2-deficient testes, no spermatogonial tumors are formed and very 
few germ cells remain (Fig6b). The difference in spermatogonial tumor incidence 
between Stra8-deficient and Stra8, Ccnd2-deficient testes is statistically significant 
(Fig6c, p value <0.01, Fishers Exact Test). From these observations we conclude that 
Ccnd2 is required for Stra8-deficient spermatogonial tumor formation. 
  
Discussion 
At one year of age most of Stra8-deficient mice on a C57BL/6NtacfBR genetic 
background have formed type A spermatogonial tumors. These tumors have the 
morphological and gene expression characteristics of both undifferentiated and 
differentiating type A spermatogonia but not those of embryonic germ cells or meiotic 
germ cells. We observed that these spermatogonial tumors are preceded by an 
increase in LIN28 positive cells, which is followed by A spermatogonia clusters that 
continuously grow along the length of the tubules as the animals age. These clusters 
were also found to correlate with tumor formation, as the genetic background with high 
cluster incidence has a high tumor incidence. The genetic background with no cluster 
incidence has a very low tumor incidence, and the background with intermediate cluster  
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incidence has intermediate tumor incidence. The tumor incidence does not correlate 
with the defect in meiosis on these same strains; all of the Stra8-deficient testes on 
these same genetic backgrounds have a defect in meiosis, but the tumor incidence is 
not consistent between the genetic backgrounds. We also observe that STRA8 
expression coincides with undifferentiated spermatogonia transitioning into 
differentiating spermatogonia. We conclude that the Stra8-deficient type A 
spermatogonial tumors are the result of a requirement for Stra8 in spermatogonial 
differentiation such that in the absence of Stra8, a subset of the undifferentiated 
spermatogonia destined for differentiation do not differentiate, leading to an increased 
number of undifferentiated spermatogonia, A spermatogonia clusters, and 
spermatogonial tumors. 
It has previously been shown that RA acts at the transition from undifferentiated 
spermatogonia to differentiating A1 spermatogonia(29, 46), and the transition from 
preleptotene to leptotene spermatocytes (meiotic initiation)(46, 135). These experiments 
took advantage of rodents on the Vitamin A Deficient (VAD) diet. Rodents on this diet 
are unable to produce RA, and are depleted of their stores until eventually RA-free, 
serving as RA-deficient models. These models are conditional, as injections of RA or 
retinol (vitamin A) restore their phenotypes. Interestingly it has been shown that VAD 
mice contain germ cells arrested as undifferentiated spermatogonia, however within 24-
48 hours after injection of RA/retinol, these germ cells dramatically induce Stra8 while 
simultaneously undergoing the transition into A1 spermatogonia. 
We have previously shown that Stra8 is required for meiotic initiation(139), and 
the present results indicate that Stra8 in addition to its role in meiotic initiation also 
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functions in spermatogonial differentiation. We think Stra8 is likely acting at the 
transition from undifferentiated spermatogonia to differentiating A1 spermatogonia based 
on its expression beginning just prior to this transition, its highly induced expression 
during VAD restoration of this transition, and the increased number and clusters of 
undifferentiated spermatogonia in Stra8-deficient testes that lead to spermatogonial 
tumors. Interestingly STRA8 is not expressed in all differentiating spermatogonia, as 
there is no STRA8 expression in In or B spermatogonia. STRA8 expression is shut off in 
these cells and then re-initiated in preleptotene spermatocytes, indicating Stra8 has 
important roles in both spermatogonia and spermatocytes. We conclude that RA acts by 
inducing Stra8 expression as one of its target genes at both the transition from 
undifferentiated spermatogonia to differentiating A1 spermatogonia and the transition 
from preleptotene to leptotene spermatocytes (Fig 8). The architecture of the testis is 
such that these two developmental transitions occur at the same time and place within 
the tubule, indicating that one pulse of RA would turn on STRA8, resulting in both 
differentiation steps simultaneously. RA simultaneously controlling these two transitions 
could represent a control mechanism of the seminiferous cycle. This leads to exciting 
possibilities for the role of RA in the control of the seminiferous cycle. 
Here we also observe that the Stra8-deficient spermatogonial tumors are 
dependent on Ccnd2. Based on the germ cell expression of Ccnd2 as undifferentiated 
spermatogonia transition to differentiating spermatogonia, and the lowered sperm count 
accompanied by a normal testicular histology in Ccnd2-deficient mice, has lead to 
speculation that they have a spermatogonial defect, possibly at the undifferentiated 
spermatogonia to differentiating spermatogonia transition(157). A function for Ccnd2 at  
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this transition in spermatogonia could explain the dependency of Stra8-deficient 
spermatogonial tumors on Ccnd2. This dependency of Stra8-deficient spermatogonial 
tumors on Ccnd2 is also interesting because of the connection between CCND2 
expression and seminomas in human testes. In humans, high CCND2 expression is 
found in both the precursor carcinoma in situ (CIS) cells and the most invasive 
seminomas, the most common type of TGCTs. Ccnd2 is found on human chromosome 
12p, a portion of the human genome that either forms an isochromosome or is amplified 
in seminomas, a step thought to be the cause of seminoma formation. The high CCND2 
expression is proposed to play a causative role in seminomas. In support of this idea, is 
in vitro work in mouse SSCs with activated RAS (which induced Ccnd2 expression) or 
overexpressing Ccnd2 and Ccne1 together, when transplanted form spermatogonial 
clusters that go on to form spermatogonial tumors in recipient testes, indicating an 
oncogenic role for Ccnd2 in mouse SSCs. 
Another interesting pathway, Kit – a tyrosine kinase receptor – and its ligand Kitl, 
also have roles in both fertility and TGCTs. In mice, it is known that Kitl-Kit signaling 
pathway is important for the transition of undifferentiated spermatogonia to 
differentiating spermatogonia. Depleting the testis of KIT by injection of a monoclonal 
antibody against KIT(34) or a splicing defect mutation in Kitl(32, 33) lead to the absence 
of differentiating spermatogonia. In addition a mutation that prevents PI3K from binding 
to KIT, thus preventing PI3K activation by KIT, also inhibits undifferentiated 
spermatogonia from transitioning to differentiating spermatogonia. KIT activating 
mutations were previously found to be associated with seminoma(72), and recent work 
using genome wide association studies identified KITL as a susceptibility gene for 
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human seminomas(91, 92). To date, the Kit-Kitl signaling pathway is the strongest 
susceptibility noted, with a known function in male fertility as well as links to TGCT 
incidence. 
In mice another signaling pathway acting on undifferentiated spermatogonia 
differentiation is the Gdnf signaling pathway. Gdnf is a growth factor required for the 
maintenance of SSCs. Its receptor, Gfrα1, is expressed by a subset of undifferentiated 
spermatogonia. Studies have shown that loss of Gdnf leads to a loss of SSC, while 
overexpression of Gdnf results in hyperproliferation of spermatogonia, forming clusters 
of spermatogonia that lead to spermatogonial tumors(15, 105, 151, 152, 161).  
The implication from the Ccnd2, Kit-Kitl, Gdnf, and Stra8 studies is that in mice 
spermatogonial tumors arise from an issue with spermatogonial differentiation. This 
suggests that testicular tumors in humans could arise from a defect in spermatogonial 
differentiation. Further research on the mechanistic basis of human TGCTs is necessary 
to see if there are similarities to these rodent models. 
 
Materials and Methods: 
Mice. Stra8 heterozygous mice (58) were crossed to either C57BL/6NtacfBR mice 
(Taconic Farms) or 129Sv/S4Jae. All experiments carried out on Stra8-deficient mice 
backcrossed to C57BL/6NtacfBR between 15 and 20 generations or 129Sv/S4Jae 10 
generations, when >99.9% of the genome is expected to be of either C57BL/6NtacfBR 
or 129Sv/S4Jae origin; all Y chromosomes and mitochondria are of C57BL/6NtacfBR or 
129Sv/S4Jae origin. Stra8-deficient males were generated by mating heterozygotes. 
Stra8 genotypes were assayed by PCR as described (58).  All experiments carried out 
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on Ccnd2-deficent or Stra8, Ccnd2-deficient mice were on a 
C57BL/6NtacfBR/129Sv/S4Jae mixed genetic background.  Stra8,Ccnd2-deficient mice 
were generated by crossing Ccnd2-deficient mice with Stra8 heterozygous mice.  The 
resulting double heterozygous mice were interbred to produce Stra8 heterozygous, 
Ccnd2-deficient males, which were subsequently mated with double heterozygous 
females.  Ccnd2 genotypes were assayed by PCR as described (159).  All experiments 
involving mice were approved by the Committee on Animal Care at the Massachusetts 
Institute of Technology. 
 
Histology. Testes were fixed overnight in Bouin's solution, embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin, hematoxylin and periodic acid Schiff 
or hematoxylin alone. 
 
Quantitative RT-PCR. Testes were stripped of the tunica albuginea, placed in TRIzol 
(Invitrogen), and stored at − 20°C. Total RNAs were prepared according to the 
manufacturer's protocol. Total RNAs were then DNase-treated by using DNA Free 
Turbo (Ambion). One microgram of total RNA was reverse transcribed by using a 
RETROscript kit (Ambion). Quantitative PCR was performed by using SYBR Green 
Core PCR Reagents (Applied Biosystems) on an ABI9700 Fast Real-time PCR machine 
(Applied Biosystems). Results were analyzed by using the delta-delta Ct method with 
use of Hprt (hypoxanthine-guanine phosphoribosyltransferase) as a normalization 
control. 
Gene 
Symbol 
Gene Name Primer Bank ID Forward Primer Reverse Primer 
Hprt hypoxanthine guanine 
phosphoribosyl 
7305155a1 TCAGTCAACGGGGGACATAAA GGGGCTGTACTGCTTAACCAG 
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transferase 
Dazl deleted in 
azoospermia-like 
 
31542549a1 
 
ATGTCTGCCACAACTTCTGAG 
 
CTGATTTCGGTTTCATCCATCC
T 
 
Clu Clusterin 7677495a1 
 
TGAAGGCATTCCCGGAAGTG 
 
CGCCGTTCATCCAGAAGTAGA 
 
Cyp17a
1 
cytochrome P450, 
family 17; steroid 17-
alpha-
monooxygenase 
6681097a1 
 
GCCCAAGTCAAAGACACCTAA
T 
GTACCCAGGCGAAGAGAATAG
A 
Lhcgr luteinizing 
hormone/choriogonad
otropin receptor 7305233a1 CGCCCGACTATCTCTCACCTA 
GACAGATTGAGGAGGTTGTCA
AA 
Rec8 REC8 homolog 
(yeast) 
31982699a2 
CTACCTAGCTTGCTTCTTCCCA 
GCCTCTAAAAGGTGTCGAATC
TG 
Sycp1 synaptonemal 
complex protein 1 
 
 
TGAGGGGAAGCTCACGGTT 
CGAACAGTGTGAAGGGCTTTT
G 
Sycp3 synaptonemal 
complex protein 3 
6755704a1 AGCCAGTAACCAGAAAATTGA
GC 
CCACTGCTGCAACACATTCAT
A 
 
Spo11 sporulation protein 11 6755624a1 CGTGGCCTCTAGTTCTGAGGT GCTCGATCTGTTGTCTATTGT
GA 
 
Dmc1 disrupted meiotic 
cDNA 1 
6753650a1 CCCTCTGTGTGACAGCTCAAC GGTCAGCAATGTCCCGAAG 
Sohlh2 spermatogenesis and 
oogenesis helix loop 
helix 2 NM_028937 21312740a1 GGGCAGGGCAGAGTAAATCTT 
Ccnd2 Cyclin D2 12841756a1 CCTGGATGCTAGAGGTCTGTG GGCCTTAGTGTGATGGGGAA 
Kit kit 26338373a1 GCCACGTCTCAGCCATCTG GTCGCCAGCTTCAACTATTAA
CT 
Utf1 undifferentiated 
embryonic cell 
transcription factor 1 
6678525a1 TGTCCCGGTGACTACGTCT CCCAGAAGTAGCTCCGTCTCT 
Gfra1 glial cell line derived 
neurotrophic factor 
family receptor alpha 
1 2624963a1 CACTCCTGGATTTGCTGATGT AGTGTGCGGTACTTGGTGC 
Nanos2 Nanos2    
Ngn3 Neurogenin3 31560622a1 AGTGCTCAGTTCCAATTCCAC CGGCTTCTTCGCTTTTTGCTG 
Oct4 POU domain, class 5, 
transcription factor 1  NM_013633 7305399a3 CAGCCAGACCACCATCTGTC 
Zbtb16 zinc finger protein 
145; Promyelocytic 
leukemia zinc finger 
21359888a1 GGGACTTTGTGCGATGTGGT ATTGCGGTGGAAGAGGATCTC 
Ccnd1 Cyclin D1 6680868a1 GCGTACCCTGACACCAATCTC CTCCTCTTCGCACTTCTGCTC 
Ccnd3 Cycllin D3 6724313a1 CGAGCCTCCTACTTCCAGTG GGACAGGTAGCGATCCAGGT 
Dppa3 developmental 
pluripotency 
associated 3 
 
21218416a1 
 
GACCCAATGAAGGACCCTGAA 
 
GCTTGACACCGGGGTTTAG 
 
Nanog Nanog homeobox 
 31338864a3 
 
CCTGATTCTTCTACCAGTCCC
A 
 
GGCCTGAGAGAACACAGTCC 
 
 
PLZF, STRA8, LIN28 Immunofluoresence. Testes were fixed overnight in Bouin's 
solution, embedded in paraffin and sectioned. Slides were dewaxed, rehydrated, and 
microwaved in 10 mM sodium citrate buffer, pH 6.0, for 5 min at 100% power followed 
by 5 min at 50% power. Slides were then treated with 5% donkey serum in 1% BSA for 
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10 min. Slides were then incubated overnight in a 1:100 dilution of mouse monoclonal 
anti-PLZF (Calbiochem) or goat anti-hLin28 (R&D Systems AF3757) in 1% BSA. Slides 
were washed with PBS and incubated for 60 min at room temperature with biotinylated 
Goat anti-mouse and 1:200 dilution of rabbit polyclonal anti-STRA8 (Abcam 49405) or 
biotinylated Horse anti-goat.  Slides were washed with PBS and incubated for 60 min 
with donkey Strepavidin secondary antibody, conjugated with FITC and donkey anti-
rabbit conjugated with Texas Red (Jackson ImmunoResearch Laboratories), at 1:200 
dilution. 
 
DAZL, MVH, PLZF, SOHLH2, STRA8 Immunohistochemistry.  Testes were fixed 
overnight in Bouin's solution, embedded in paraffin, and sectioned. Slides were 
dewaxed, rehydrated, and microwaved in 10 mM sodium citrate buffer, pH 6.0, for 5 min 
at 100% power followed by 5 min at 50% power.   
 Slides were then incubated in 5% BSA, followed by a 30-min incubation with primary 
antbody (Mouse anti-hDAZL (AbD Serotec) 1:500, Rabbit anti-MVH (a gift from Toshiaki 
Noce, Tokyo, Japan) 1:1000, PLZF (Calbiochem) 1:100, SOHLH2 (a gift from 
Aleksandar Rajkovic, Houston, Texas) 1:100, STRA8 1:200 Abcam49405). Slides were 
then washed with PBS and incubated with anti-mouse secondary antibody conjugated 
with horseradish peroxidase (ImmunoVision Technologies). Peroxidase activity was 
visualized by using 3,3-diaminobenzidine-tetrahydrochloride (Sigma) as substrate. 
Sections were counterstained with hematoxylin. 
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Chapter 4 
 
Conclusions and Future Directions 
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RA induction of Stra8 regulates meiotic initiation in both sexes 
In the course of my thesis work I have characterized the function of Stra8, a 
retinoic acid (RA) responsive gene, in spermatogenesis. Through analysis of Stra8-
deficient testes, I have discovered that similar to the role Stra8 plays in the embryonic 
ovary, Stra8 is required for meiotic initiation in the postnatal testis (Chapter 2).  This 
conclusion is supported by observations of postnatal Stra8-deficient testes. Stra8-
deficient testes display an absence of meiotic chromosome condensation (histology), 
meiotic chromosome pairing (lack of SYCP3 and REC8 loading), and meiotic 
recombination (lack of Spo11, Dmc1, and γ-H2AX expression). In the embryonic ovary, 
Stra8 is required for pre-meiotic DNA replication; Stra8-deficient germ cells have 2C 
DNA content while their wildtype counterparts acquired 4C (58). Based on these 
observations, Baltus et. al. argue that the decision to enter meiosis occurs prior to this 
replication event and this replication is part of meiosis. In contrast, in the Stra8-deficient 
testis, we observed preleptotene spermatocytes incorporating BrdU, indicating that they 
do replicate their DNA. It is not clear whether this replication event is a mitotic or a 
meiotic DNA replication, as we do not have a marker that distinguishes between the 
two. However, two lines of evidence suggest that the Stra8-deficient preleptotene 
spermatocytes are undergoing a mitotic DNA replication. First, meiotic cohesin proteins 
are loaded during pre-meiotic DNA replication(124, 125), and REC8, a meiosis-specific 
cohesin protein, is not properly loaded onto the chromosomes in the absence of Stra8. 
This leads me to conclude that the replication happening in the absence of Stra8 is 
either mitotic or is an aberrant pre-meiotic DNA replication. Second, on a mixed genetic 
background, some of the Stra8-deficient preleptotene spermatocytes divide mitotically. 
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Stra8-deficient spermatocytes display a metaphase-like histology, containing 40 
univalent chromosomes, in contrast to the 19 bivalents (plus X and Y chromosomes) 
found during meiotic metaphase I (140). I do not observe mitotic spermatocytes in 
Stra8-deficient testes on the C57BL6 genetic background, presumably because the 
preleptotene spermatocytes apoptosed prior to this mitotic division. The presence of 
these mitotic spermatocytes indicates that, in the absence of Stra8, preleptotene 
spermatocytes continue to divide mitotically, and that Stra8 is required for pre-meiotic 
DNA replication in the testis. On the basis of these two lines of evidence I conclude that 
the decision to enter meiosis occurs prior to DNA replication in both males and females. 
 Stra8 expression is regulated by RA levels in embryonic gonads(111, 112). 
Cyp26b1, a P450 enzyme that degrades RA, is expressed in the embryonic testis but is 
not expressed in the embryonic ovary(162). As the levels of Cyp26b1 decrease in the 
embryonic testis, a second gene, Nanos2, begins its expression and maintains the 
absence of Stra8 through an unknown mechanism(163). As a result, RA levels are 
predicted to be high in the embryonic ovary where Stra8 is expressed and low in the 
embryonic testis where it is not expressed. This led to the proposal that RA acts as a 
meiotic inducer by turning on Stra8 expression in the embryonic ovary; male germ cells 
do not enter meiosis in the embryo because they are not exposed to RA. Recent work 
has challenged this model of RA inducing Stra8 expression, using Raldh2-deficient mice 
to study embryonic ovaries in the absence of RA production. The authors find that the 
Raldh2-deficient embryonic ovaries still express Stra8, and conclude that Stra8 
expression is not dependent on RA. However, there are several assumptions taken with 
this conclusion. First, it is assumed that Raldh2-deficiency completely removes all RA 
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from the embryonic ovary. However, expression studies of the embryonic ovary have 
shown that Raldh1 is expressed (Mark Gill and Jake Meuller, unpublished) and could 
produce RA in the absence of Raldh2. Second, the authors assume that their RARE-
lacZ transgene is able to detect the entire physiologic range of RA from 10nM to 100nM. 
However, the authors only show that they can detect as low as 25nM RA using this 
method, leaving open the possibility that less than 25nM RA could be present in the 
Raldh2-deficient embryonic ovary and would not be detected using the RARE-lacZ 
transgene. Third, the Raldh2-deficient mice die in utero prior to E13.5, the timepoint of 
Stra8 expression, due to effects of the deficiency in somatic cells throughout the body. 
In order to observe germ cell development at E13.5 in the Raldh2-deficient embryonic 
ovary, RA injections were given up to two days prior to analysis of Raldh2-deficiency. 
Given it is not clear whether the authors could detect levels of RA below 25nM, it is also 
unclear whether all of the RA injected would be degraded in this two day span. Taken 
these assumptions together, it is not clear whether the Raldh2-deficient mice were 
depleted of RA, and therefore the authors have not shown that induction of Stra8 
expression in the embryonic ovary is independent of RA.  
According to the RA induction model, increasing RA levels in the embryonic 
testis should result in male germ cells entering meiosis. Cultured embryonic testes were 
treated with an inhibitor of Cyp26b1(164), and Cyp26b1-deficient testes(165, 166) were 
examined in vivo. In both cases, loss of Cyp26b1 function led to an increase in Stra8 
expression presumably due to increased RA levels. The work in cultured testes was 
time-limited and unable to address what happened to the now-Stra8 expressing cells, 
but the fate of these cells was characterized in the Cyp26b1-deficient testes. These 
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germ cells, unlike their wildtype counterparts, do not enter a G0 arrest, but instead 
express meiotic markers SYCP3 and Dmc1, and load SYCP3 onto the lengths of their 
chromosomes(165, 166). However, these cells are not able to progress further through 
meiosis and soon apoptose, leaving germ cell deficient testes. These results argue that, 
while RA and Stra8 are required to enter meiosis, they are not sufficient to engage the 
entire meiotic process. We conclude that Stra8 expression in response to robust RA 
levels is the mechanism that governs the decision to enter meiosis. 
 
RA induction of Stra8 regulates Aal to A1 transition 
 I also demonstrated a role for Stra8 in spermatogonial differentiation. I have 
shown that Stra8-deficient testes accumulate undifferentiated spermatogonia as early 
as ten days of age, as shown by counts of LIN28 expressing cells. These accumulated 
undifferentiated spermatogonia later form clusters of cells in rare tubules as early as 
one month. These clusters continue to expand along the length of the tubule within the 
basal compartment. Ultimately, these clusters invade the luminal compartment of the 
tubule as well as the interstitium, forming testicular germ cell tumors at one year of age.   
STRA8 protein is not expressed by the majority of undifferentiated 
spermatogonia; it is only expressed in rare transitional Aal cells (Chapter 3, Figure 3). 
STRA8 protein expression in transitioning Aal cells suggests that STRA8 could be acting 
at the transition from Aal to A1. Interestingly, RA is required for this transition(29). In 
vitamin A deficient (VAD) mice, which are depleted of RA, the germ cells arrest as Aal. 
Upon injection of RA or retinol (the dietary precursor to RA), Stra8 expression strongly 
increases and all Aal synchronously become A1(111). These data lead to the conclusion 
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that RA acts at this transition by turning on Stra8 as one of its target genes. This 
conclusion is supported by the observation of accumulated undifferentiated 
spermatogonia in the Stra8-deficient testes, despite an absence of STRA8 protein in the 
majority of undifferentiated spermatogonia. 
 
RA induction of Stra8 regulates seminiferous cycle 
Similar to the embryonic ovary, RA also plays a role in meiotic initiation in 
postnatal males. Observations in VAD rats, prior to the complete depletion of RA and 
arrest of Aal, have shown that the germ cells are also arrested as preleptotene 
spermatocytes(46). Rats kept on the VAD diet ultimately lead to the loss of the 
preleptene spermatocytes and a complete arrest at Aal. Both the Aal spermatogonia and 
the preleptotene spermatocyte arrests can be rescued with injections of RA, which 
result in simultaneous transitions into A1 spermatogonia and leptotene spermatocytes 
respectively(46). 
As the VAD diet takes several months to fully deplete the mouse testis of RA, 
several rounds of spermatogenesis complete before RA is fully depleted. In order to 
investigate RA function in the first round of spermatogenesis, Lrat-deficient mice are 
used(47). Lecithin retinol acyltransferase, Lrat, is an enzyme responsible for the 
formation of retinyl esters, a step on the path to the production of retinoic acid from 
retinol. Lrat-deficient mice on a VAD diet result in a RA-deficient testis around six days 
after birth, based on Stra8 expression. The loss of RA at this early time point enables 
the study of RA-deficiency during the first round of spermatogenesis.  
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Li et. al. report a requirement for RA in meiotic initiation. This was shown by an 
absence of meiotic chromosome condensation, and an absence of SYCP3 expression.  
This finding is significant because the preleptotene spermatocytes are coming from RA-
sufficient spermatogonia. The spermatogonia in the first round were observed in normal 
numbers overall, and the undifferentiated spermatogonia were specifically unchanged in 
number. This indicates RA also acts in meiotic initiation in the postnatal testis, 
independently of its role at the Aal to A1 transition. I conclude that the mechanism of RA 
induction of Stra8 similarly regulates the decision to enter meiosis in both the postnatal 
testis and the embryonic ovary. In addition, I conclude that RA induction of Stra8 
controls two transitions during spermatogenesis: the decision to enter meiosis 
(preleptotene to leptotene), and the differentiation of undifferentiated spermatogonia (Aal 
to A1). 
 These two roles for RA and Stra8 during spermatogenesis lead to some 
interesting speculation about the control of the seminiferous cycle. Spatially, 
spermatogenesis develops along the length of the tubule as well as towards the center 
or lumen of the tubule. Along the length of the tubule, the development of germ cells is 
continuous, with A spermatogonia progressing into In spermatogonia, then to B 
spermatogonia, and then preleptotene spermatocytes, etcetera. However, moving from 
the outer rim or basal lamina towards the lumen (a tubule cross-section), the 
development of the germ cells is discontinuous, with spermatogonia progressing into 
spermatocytes and then to spermatids. The development is highly organized in this 
dimension as the germ cells are consistently found in reoccurring associations with 
each other. For example, A1 spermatogonia are always associated with preleptotene 
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and pachytene spermatocytes and stage 7, 8 and 16 spermatids, while A2 
spermatogonia are always found with leptotene and pachytene spermatocytes and 
stage 9 and 10 spermatids (Figure 1). These consistent associations are thought to 
occur because of the regularity in the start of spermatogenesis. A1 spermatogonia are 
formed every 8.6 days, and take 8.6 days to develop to the point of preleptotenes 
entering meiosis, which results in the constant association between A1 spermatogonia 
and preleptotene spermatocytes(2). Together, this means that the two points in 
spermatogenesis controlled by both RA and Stra8 occur at the same time and the same 
place. This indicates that RA could play a role in the regulation of the seminiferous 
cycle. 
A few pieces of evidence indicate that RA acts to regulate this cycle. First, RA 
can affect the seminiferous cycle. RA restoration of VAD testes synchronizes 
spermatogenesis across the testis(137). The result of this is that sperm are produced 
only every 8.6 days, in contrast to the normal, continuous production of sperm. In 
addition, RA treatment of neonatal mice also synchronizes spermatogenesis, similar to 
the RA-treated VAD testes(167). Second, one of the transitions in which RA acts marks 
the beginning of the seminiferous cycle. This transition, the Aal to A1 transition, is when 
the undifferentiated spermatogonia become the first of the differentiating 
spermatogonia. The undifferentiated spermatogonia are unique in that they are present 
throughout the cycle, unlike all the other germ cell types, which appear only in distinct 
portions of the cycle. The transition into differentiating spermatogonia is also a transition  
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into regulated cellular divisions. The undifferentiated spermatogonia divide without 
regard to the seminiferous cycle, whereas the differentiating spermatogonia only divide 
during particular portions of the cycle, within their germ cell associations. The Aal to A1 
transition appears to act as a control point in spermatogenesis, as the majority of known 
spermatogonial defects occur in the transition into A1 spermatogonia, hinting that this 
step is highly regulated. Third, these two RA-controlled transitions occur at the same 
place and the same time within the tubule, and are also regulated by Stra8, indicating 
that a common regulatory mechanism governs these decisions. The spatial and 
temporal coordination of these two transitions by the same regulatory mechanism 
indicates that RA induction of Stra8 could act as part of the regulatory mechanism 
controlling the seminiferous cycle. Tightly regulated control of RA in the tubule could set 
the tempo of the seminiferous cycle. Further work is needed to assess whether RA can 
explain the entirety of the seminiferous cycle, and to uncover additional targets of RA 
involved in regulating the seminiferous cycle. 
 
Deletions of RA receptors do not recapitulate Stra8-deficient testes phenotype 
 A model for RA action is that of RA binding to its receptors, RARs and RXRs, 
and inducing gene expression of target genes. However, individual deletion of RAR and 
RXR isoforms (Rarα, Rarβ, Rarγ, Rxrβ, and Rxrγ) does not recapitulate the Stra8-
deficient phenotype with defects in spermatogonial differentiation and meiotic initiation 
(Rxrα-deficient animals do not survive postnatally, precluding analysis of 
spermatogenesis). A simple explanation for this is that these receptors act redundantly 
in the germline. There is evidence that deletion of Rarα results in increased Rarβ and 
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Rarγ expression(168). Combined deletion of RARs and RXRs has only been done in 
Sertoli cell specific deletions, leaving open the possibility that these receptors act 
redundantly in the germline. However evidence presented by Vernet et. al., demonstrate 
that preleptotene spermatocytes do not express any RARs nor RXRs at either the RNA 
or the protein level (55). This would explain why deletions of these receptors would not 
recapitulate the Stra8-deficient meiosis phenotype, but raises the question of how RA 
induces Stra8 expression in preleptotene spermatocytes. In contrast to Vernet et. al., 
microarray analysis of FACS sorted preleptotene spermatocytes shows RNA expression 
of at least Rarα, Rarγ, Rxrβ, and Rxrγ(169). Vernet et. al. also found that A 
spermatogonia only express Rarγ, and B spermatogonia do not express any RARs nor 
RXRs. This also conflicts with microarray analysis of A and B spermatogonia, which 
have been shown to express all RARs and RXRs at the RNA level(169). I propose that 
spermatogonia and preleptotene spermatocytes do express RARs and RXRs, but at a 
level below that of detection using the methods utilized by Vernet et. al., and that these 
receptors act redundantly in the germline.  
Alternative explanations are that there are yet uncharacterized RA receptors 
expressed in germ cells, or that RA does not act directly on Stra8 to induce its 
expression. These possibilities seem unlikely based on Chip-Seq analysis of RAR 
binding sites in embryonic stem (ES) cells. In ES cells, RAR was found to always be 
bound to a RARE element in the Stra8 promoter(170), indicating that the effect of RA on 
Stra8 is direct and through the RARs. Additional research is required to see if this 
interaction between RARs and the Stra8 promoter is true in spermatogonia and 
preleptotene spermatocytes. 
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 Stra8-deficient tumors result from a defect in Aal to A1 transition 
I have also shown that Stra8 acts as a tumor suppressor gene in spermatogonia. 
Stra8-deficient testes form spermatogonial tumors that arise from early accumulations 
of undifferentiated spermatogonia. I think these accumulations result from a defect in 
the differentiation of undifferentiated spermatogonia. I have also shown that these 
Stra8-deficient spermatogonial tumors are dependent on Ccnd2. Ccnd2 is implicated in 
human TGCTs through its expression in the precursor cells and in the invasive tumor 
cells, and its presence on human chromosome 12p, a region of the genome that is 
either amplified or forms an isochromosome in TGCTs. It has also been proposed that 
in mice Ccnd2 plays a role in spermatogonial differentiation at the Aal to A1 transition, 
based on its expression beginning as Aal transition into A1 spermatogonia (157). Ccnd2-
deficient male mice are fertile, but have a lowered sperm count, indicating a defect in 
spermatogenesis. A plausible explanation could be that Ccnd2 is acting at the Aal to A1 
transition, but is not completely required, similar to Stra8. The characterization of 
Ccnd2-deficient testes by both Sicinski et. al. and I were done on a mixed genetic 
background, so it is possible that moving the Ccnd2 null allele onto a pure C57BL6 
genetic background will enhance the defect in spermatogenesis, as most fertility 
phenotypes are more severe on the C57BL6 background. 
 If Ccnd2 is acting at the Aal to A1 transition, it would implicate this transition in the 
formation of the Stra8-deficient spermatogonial tumors, further supporting a role for 
Stra8 in this transition. Our observations of germ cell loss in the Ccnd2, Stra8 double 
knockout testes support the idea of Ccnd2 acting at the Aal to A1 transition. In one year 
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old Ccnd2-deficient, Stra8-deficient testes, very few germ cells remain, indicating that 
the absence of Ccnd2 in Stra8-deficient germ cells enhances the defect at the Aal to A1 
transition. 
Kit/Kitl signaling pathway acts at the Aal to A1 transition in mice, with Aal 
spermatogonia unable to transition to A1 spermatogonia in the absence of this signaling 
pathway(32-35). Kit and Kitl are the strongest susceptibility genes known for human 
TGCT, with a known function in male fertility and association with TGCT incidence(91, 
92). The Stra8-deficient spermatogonial tumors do express Kit (Chapter 3, Figure 2), so 
if the Aal to A1 transition is involved in the formation of these tumors, I would expect 
tumor formation to be dependent on the Kit/Kitl signaling pathway. It would be 
interesting to observe the tumor phenotype of mice carrying the Sl17h allele and are 
deficient for Stra8, as I would predict no spermatogonial tumors would form in these 
mice. 
 
Stra8 is required for teratoma formation 
Stra8 is also required for testicular teratoma formation (Appendix 2). Mice on the 
129 genetic background spontaneously form testicular teratomas, and are a model for 
human teratomas(72). These tumors are distinct from the spermatogonial tumors that 
form in the Stra8-deficient mice in that they contain embryonal carcinoma cells, and at 
least one of the embryonic germ layers (mesoderm, endoderm, ectoderm). I have 
shown that these testicular teratomas are dependent on Stra8 (Appendix 2). This raises 
some questions as teratomas originate from embryonic male germ cells, which do not 
express Stra8. Perhaps inappropriate expression of Stra8 in embryonic male germ cells 
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initiates teratomas. This opens up a new possibility for the fate of the embryonic germ 
cells exposed to RA in the Cyp26b1-deficient testes. It is known that Cyp26b1-deficient 
embryonic male germ cells do express Stra8 and some meiotic genes, but they also 
continue to divide mitotically and apoptose(164-166). Unfortunately the Cyp26b1-
deficient mice do not survive long enough after birth to observe surviving male germ 
cells in the Cyp26b1-deficient postnatal testis.  It would be interesting to use a 
conditional allele to specifically delete Cyp26b1 in the testis, and observe the fate of 
male germ cells. It is possible that surviving germ cells would form a teratoma. 
 
Future Directions – questions stemming from my work on Stra8 during 
spermatogenesis 
 
Does RA act directly on Stra8 to induce its expression? 
 It has been demonstrated that RA induces Stra8 expression in germ cells, which 
is thought to occur by RA binding to its receptors, RARs and RXRs, and inducing gene 
expression of Stra8. However, there is no direct evidence in either spermatogonia or 
preleptotene spermatocytes whether RA induces Stra8 by binding to RARs/RXRs on 
the Stra8 promoter, as the binding of RARs to the Stra8 promoter has only been 
demonstrated in ES cells(170). In order to determine whether RA acts directly on Stra8 
to induce its expression in these cell types, RAR Chip seq should be done. In this 
technique, the DNA fragments where a protein of interest has bound are sequenced 
and then aligned to the genome. In this way, one can locate sequences where a protein 
of interest binds. In order to determine the RAR binding sites in spermatogonia and 
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preleptotene spermatocytes these cells have to be isolated from the testis. Recent 
reports have shown that FACS can isolate pure populations of preleptotene 
spermatocytes(169), in addition to previous work isolating undifferentiated 
spermatogonia and differentiating A spermatogonia. The RAR binding sites found in 
these isolated cell types could then be compared to RA-treated isolated cells. This work 
will determine whether RARs bind to the Stra8 promoter in cell types known to express 
Stra8 and where Stra8 functions. 
 
Is STRA8 sufficient for spermatogonial differentiation and/or meiotic initiation? 
 My work has shown that Stra8 acts in spermatogonial differentiation and meiotic 
initiation, but we do not know if Stra8 is sufficient for these processes. One way of 
testing Stra8 sufficiency is make a tamoxifen-inducible Stra8 mouse. In this way, Stra8 
expression is induced by injections of tamoxifen. This mouse model could be used to 
turn on expression of Stra8 in undifferentiated spermatogonia, and in B spermatogonia. 
If Stra8 is sufficient for spermatogonial differentiation, then ectopic expression of Stra8 
in undifferentiated spermatogonia would cause expression of Kit, Ccnd2, and Sohlh2. In 
addition, these ectopic Stra8 expressing spermatogonial cells would enter meiosis 
faster than the 8.6 day timing normal for undifferentiated spermatogonia to develop into 
preleptotene spermatocytes entering meiosis. If Stra8 is sufficient for meiotic initiation, 
then ectopic expression of Stra8 in B spermatogonia should cause these cells to enter 
into meiosis by loading meiotic cohesin proteins and synaptonemal complex proteins 
onto their DNA, and by undergoing meiotic recombination. 
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 The Stra8-deficient spermatogonial tumors also present a unique opportunity to 
study spermatogonial differentiation. An interesting experiment would be to give Stra8 
expression back to either the tumor cells or the clusters of undifferentiated 
spermatogonia, and see if the cells are able to differentiate, and develop into 
preleptotene spermatocytes and enter meiosis. This could also be done using a 
tamoxifen-inducible Stra8 mouse. Additionally these tumor and cluster cells could be 
treated with RA to test the capability of these cells to respond to RA without being able 
to induce Stra8 expression. This could give insight into RA effects on spermatogonia 
outside of Stra8 induction. Characterizing the tumor and cluster cells before and after 
RA and Stra8 treatments will give further insight into spermatogonial differentiation. 
 
Is the Stra8-deficient defect in meiotic initiation a downstream consequence of 
the defect in spermatogonial differentiation? 
 The Stra8-deficient testis has defects at two points during spermatogenesis, in 
spermatogonial differentiation and in meiotic initiation. It is not clear whether the defect 
in meiotic initiation is a consequence of the prior defect in spermatogonial 
differentiation. In order to determine whether the meiotic initiation defect is independent 
of the spermatogonial differentiation defect, I suggest two lines of experiments. First, I 
suggest further characterization of Stra8-deficiency on the inbred line 129Sv/S4Jae. My 
characterization of the Stra8 phenotype on this genetic background has suggested that 
Stra8 is not acting in spermatogonial differentiation but is only acting in meiotic initiation 
on this background. Further characterization is needed to see if spermatogonial 
differentiation is unaffected by Stra8-deficiency on the 129 genetic background. If Stra8 
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does not act in spermatogonial differentiation on the 129 genetic background, this would 
support the independence of Stra8’s function in meiotic initiation from its function in 
spermatogonial differentiation.  
 Alternatively, a conditional Stra8-deficient mouse could be made in order to 
specifically delete Stra8 in B spermatogonia/preleptotene spermatocytes prior to meiotic 
initiation. Flox sites could be inserted into the introns surrounding critical exons of Stra8, 
such that when excised using a specific Cre, full length Stra8 would no longer be 
transcribed. One such ES cell line has already been developed by the European Mutant 
Mouse Cell Repository (EuMMCR). These ES cells are designed with flox sites 
surrounding exons 3 and 4 of the Stra8 locus. These ES cells can be used to create 
Stra8 conditional knockout mice, which would need to be crossed with a Cre mouse line 
active specifically in B spermatogonia/preleptotene spermaaotyctes. Unfortunately no 
such Cre mouse line exists currently. This leaves two options, making such a Cre, or 
using an inducible ubiquitous Cre. The Stra8 conditional knockout mice would be 
crossed with an inducible ubiquitous Cre line, and then progeny of the cross would be 
injected with tamoxifen during formation of B spermatogonia. Then the preleptotene 
spermatocytes that form would be observed in the following 1-3 days post injection to 
determine whether they can enter meiosis. A caveat of the ubiquitous Cre approach is 
that the spermatogonia would also be Stra8-deficient, and given that these cells are in 
the same compartment of the testis with the preleptotenes, it remains possible that 
Stra8-function in these cells is necessary for meiotic initiation in preleptotene 
spermatocytes. (The germ cell specificity of Stra8 expression prevents a phenotype in 
somatic cells.)  Alternatively, making a new mouse Cre line that acts specifically in B 
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spermatogonia would remove the formal possibility that Stra8 deficiency in the 
spermatogonia results in the meiotic defect. However, first it would be necessary to 
identify a potential gene whose expression would allow for this. This gene could be 
identified by comparing gene expression in sorted germ cell populations and looking for 
genes uniquely expressed in B spermatogonia/preleptotene spermatocytes. 
 
Do the Stra8-deficient clusters of undifferentiated spermatogonia form the Stra8-
deficient spermatogonial tumors?  
 I have shown that formation of clusters of undifferentiated spermatogonia is 
correlated with formation of spermatogonial tumors in the Stra8-deficient mice. In order 
to determine whether these clusters will ultimately form spermatogonial tumors, lineage 
tracing should be done. Ngn3 is a marker of undifferentiated spermatogonia, and Ngn3-
Cre and Ngn3-CreER mouse lines already exist, which could be crossed with a reporter 
line (ex. R26R – a lacZ reporter line) and the Stra8 mutation. The tumors forming in 
Ngn3Cre, R26R, and Stra8-deficient mice could be assayed for LacZ expression, which 
would indicate that the tumor cells originated from an Ngn3 expressing cell, i.e. from 
undifferentiated spermatogonia. This same assay could be used to show that the 
clusters originate from undifferentiated spermatogonia. 
 It is possible that part of the transition from a spermatogonial cluster into a 
spermatogonial tumor is the loss of adhesion to the Sertoli cells. In order to test for a 
dependence on loss of adhesion, a tamoxifen-inducible E-cadherin mouse should be 
made and crossed to the Stra8-deficient mouse in order to over-express E-cadherin. 
Increased cadherin expression has been shown to increase adhesion of the over-
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expressing cells to each other(171), which indicates that forced over-expression of 
cadherin could cause the germ cells and sertoli cells to increase their adhesion to each 
other. Loss of E-cadherin in human testicular tumors is postulated to be part of tumor 
pathogenesis(172). Increasing adhesion in the Stra8-deficient testes by forcing 
continued expression of E-cadherin could limit the growth of the spermatogonial cells 
and perhaps suppress the spermatogonial tumors.  
 
What is Stra8’s molecular function?  
 I have shown roles for Stra8 in meiotic initiation, in spermatogonial differentiation, 
as a tumor-suppressor gene and teratoma formation. The next step is to determine the 
molecular function of STRA8 in order to uncover how Stra8 acts in these processes. A 
few studies have begun to unravel possible molecular functions for STRA8. One 
possibility is that it is a transcription factor. The predicted protein structure of STRA8 
includes a basic helix-loop-helix domain, a known transcription factor domain(173). In 
support of the transcription factor hypothesis, STRA8 protein does localize to the 
nucleus, as well as to the cytoplasm (Chapter 3, Figure 3). Recent work has shown in 
vitro that the Stra8 sequence contains functional nuclear export and nuclear import 
sequences(63). These sequences could serve to regulate STRA8 function, by shuttling 
the protein in and out of the nucleus to allow/prevent its function in the nucleus. These 
in vitro studies also found that STRA8 can bind to DNA(63), supporting the possibility 
that STRA8 acts as a transcription factor. 
 In order to explore this possibility, several follow up studies should be done. First, 
it should be determined where in the genome STRA8 binds. This can be assessed by 
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Chip-Seq. Once the locations of STRA8 binding are revealed, they can be compared to 
genome-wide expression analysis of Stra8-deficient cells of interest. Potential targets of 
Stra8 transcriptional regulation could be found by identifying genes whose promoters 
are bound by STRA8, and whose RNA expression changes in the absence of Stra8.  
 In addition to determining potential transcriptional targets of Stra8, a second 
method to tease apart Stra8 molecular function would be to find STRA8 interacting 
proteins. If Stra8 were a transcription factor, one would expect to find that STRA8 
interacts with transcription-related proteins, such as RNA polymerase, DNA helicase, or 
other transcription factors. In order to find STRA8 interacting proteins, IP-Mass Spec 
should be done. In this assay, a co-immunoprecipitation is first done, using an anti-
STRA8 antibody to pull STRA8 protein down from a protein tissue lysate in conditions 
that will retain protein-protein interactions. This would pull down complexes of proteins 
that contain STRA8, and proteins that interact directly with STRA8. Immunoprecipitated 
proteins are then run through a mass spectrometer to identify each individual protein. In 
this way, proteins that interact with STRA8 can be identified and used to find possible 
molecular functions of STRA8. 
 We know that Stra8 is acting in meiotic initiation in both sexes, in the embryonic 
ovary and in the postnatal testis. This raises the question of whether Stra8 acts in the 
same way in both sexes to regulate the decision to enter meiosis. Meiosis is different in 
males and females. Males continue through both meiotic divisions without pausing, 
while females arrest twice, and do not complete the second meiotic division until after 
fertilization by the sperm cell. It is not known whether these distinct meiotic processes 
are initiated during entry into meiosis. Stra8 may interact with different proteins in the 
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ovary to initiate meiosis than those in the postnatal testis. These sex-specific protein 
interactions may enable the temporally controlled meiosis in females and the continuous 
meiosis in males. 
 Stra8 also plays two roles in the postnatal testis, in spermatogonial differentiation 
and in meiotic initiation. It is not known whether the two roles that Stra8 plays in the 
postnatal testis are two distinct roles, or one role. Stra8 could be acting in meiotic 
initiation in both spermatogonia and in preleptotene spermatocytes. The differentiating 
spermatogonia could be already committed to meiosis. The differentiating 
spermatogonia are distinguished from one another solely by subtle chromatin changes 
visible by histology, however the type A differentiating spermatogonia are not distinct 
from one another. The type A differentiating spermatogonia are distinguished only by 
the more differentiated germ cells they are found associated with. There are no 
published gene expression differences between differentiated spermatogonia, which 
leads to the question of whether these cells represent different cell states, if they are 
merely a uniform population of mitotic cells, whose purpose is to increase germ cell 
number prior to meiosis, or if both are true. Alternatively, it remains possible that these 
differentiating spermatogonia are in some way becoming competent for meiosis. It is not 
known if these mitotic divisions are necessary for the cells to become competent for 
meiosis, or if all spermatogonia are already competent for meiosis but are not exposed 
to the meiosis-promoting signals.  
RA-treated VAD testes show an increase in Stra8 expression, indicating that 
undifferentiated spermatogonia will respond to RA by turning on Stra8(111). Dmrt1 is 
thought to suppress RA signaling in undifferentiated spermatogonia, and Dmrt1-
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deficient undifferentiated spermatogonia aberrantly express STRA8(174). These Dmrt1-
deficient spermatogonia progress into meiosis roughly 1-2 days faster than the timing in 
wildtype cells, indicating that transitioning from undifferentiated spermatogonia into a 
preleptotene spermatocyte does not have to take 8.6 days. This could mean that the 
differentiating spermatogonia are not all necessary for meiotic competence. However, 
although RA-treated VAD testes show an increased expression of meiotic genes such 
as Rec8 (data not published), they do not enter meiosis until after preleptotenes have 
formed under the normal 8.6 day timing. This effect of RA on undifferentiated 
spermatogonia is consistent with studies of RA effects on embryonic male germ 
cells(164-166) where meiotic gene expression is induced, but full-scale meiosis is not. 
The RA-treated VAD testes also show an increased Dmrt1 expression (unpublished 
data). The persistent Dmrt1 expression could explain why these RA treated 
spermatogonia do not undergo meiosis until after developing through the differentiating 
spermatogonia under the normal 8.6 day timing, as they need to stop expressing Dmrt1 
in order to achieve meiotic competence. Dmrt1 expression in the germ cells is present 
up until meiosis in both sexes(175), indicating that meiotic competence is not achieved 
until loss of Dmrt1 expression in both sexes. The Dmrt1 expression in male embryonic 
germ cells would also explain the response of male embryonic germ cells to RA, where 
they express meiotic genes but do not enter full-scale meiosis. Taking these results 
together, this indicates that while RA and Stra8 are required for meiotic initiation, they 
are not sufficient for meiotic competence, which is acquired, at least in part, by loss of 
Dmrt1 expression.  
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 Exploring these questions of Stra8 function in different cell types will involve 
performing the Chip-Seq and IP-Mass Spec experiments in the relevant cells types to 
characterize cell states and comparing the results. For example, a comparison of 
STRA8 binding sites and protein interactors in embryonic ovarian germ cells just prior to 
meiotic entry can be compared to those in the preleptotene spermatocytes of the 
postnatal testis to see if Stra8 is functioning the same in both sexes to regulate meiotic 
entry. Additionally these results can be compared to those of A1 spermatogonia, to 
distinguish between a distinct or consistent role for Stra8 in these cells. In addition, 
comparing STRA8 binding sites in these three cell types to gene expression differences 
in the absence of Stra8 in these three cell types, will reveal potential cell-type specific 
transcriptional targets of Stra8, and gives clues as to the function of Stra8 in different 
cell types. 
 There are several technical hurdles in order to achieve cell-type specific 
experiments. The embryonic gonad is not a large tissue, and the germ cells within are 
not a large population of cells, so it will be extremely challenging to obtain enough 
material for these experiments. Ideally the germ cells would be sorted out from the 
gonads to remove somatic cell contamination, which increases the difficulty in obtaining 
enough material. At this time, the amount of starting material required exceeds the 
predicted maximum that can be obtained from the embryonic gonads. 
In the postnatal testis, the tissue is sufficiently large as to provide enough 
material, but the germ cells are developing at different stages concurrently. In order to 
obtain specific germ cell types, and to remove somatic cell contamination, the germ 
cells would also have to be sorted from the testis similar to the embryonic ovary. 
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Currently the methods of sorting out distinct germ cell types can isolate preleptotene 
spermatocytes, but cannot separate different type A spermatogonia. It is possible to sort 
out different type A spermatogonia in the first round of spermatogenesis by collecting 
germ cells at different ages, as the germ cells present only include spermatogonia in the 
first week after birth. This would allow for these experiments in the postnatal testis, 
specifically preleptotene spermatocytes and A1 spermatogonia. 
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Appendix 1 
 
 
 
Stra8-deficient spermatogonial tumors are a 
model for human seminoma 
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The following appendix is an extended discussion of the Stra8-deficient tumors 
discussed in Chapter 3 in relation to human testicular cancer. The spermatogonial 
tumors that form in Stra8-deficient testes have a histology that is consistent with the 
seminoma TGCTs that form in humans (Dr. Leendert Looijenga and Dr. George Mutter, 
personal communication). Currently there is no accepted animal model of human 
seminoma. Here I will discuss and critique the current model for pathogenesis of human 
seminomas and discuss a new model based on this critique as it relates to Stra8-
deficient spermatogonial tumors. 
 
Seminomas 
The current model for human seminomas states that seminomas arise from an 
embryonic germ cell, based on several observations. Etiologic studies of TGCT 
incidence in birth cohorts found two cohorts. Those born just prior or during World War 
II were at lower risk for testicular cancer than expected from the generally increasing 
trend of all the other cohorts studied. These findings were taken to mean that testicular 
cancer is initiated early in life as the timing of the birth changed the risk for TGCTs(176). 
However, given that the men in these birth cohorts are the same age their entire life, it is 
difficult to pinpoint embryonic development as the sole explanation for this finding. 
The embryonic germ cell interpretation of the birth cohort studies was found to be 
consistent with reports of carcinoma in situ (CIS) cells as the cell of origin for 
seminomas and the characterization of these cells. CIS cells were first identified in 
testicular biopsies from two infertile male patients(177). One patient underwent a 
second biopsy sixteen months later and an embryonal carcinoma tumor was 
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discovered. In the other patient, a second biopsy was taken and additional CIS cells 
were observed, but no tumor. The testis was removed as a prophylatic measure, and 
was discovered to contain an embryonal carcinoma tumor. The incidence of these CIS 
cells is similar to the lifetime risk of TGCTs(178), and are thought to always become a 
TGCT once formed(179). These CIS cells are thought to be a neoplastic counterpart of 
primordial germ cells (PGCs) or gonocytes based on similar gene expression(180). Also 
in support of an embryonic germ cell origin for human seminomas specifically, is the 
biallelic expression of H19 and IGF2(181), the relatively high telomerase activity(182), 
and the gene expression of embryonic germ cell markers such as Oct4, Nanog, and 
Plap in these tumors(180). 
 After the formation of CIS cells, the progression to invasiveness and seminoma 
formation is thought to involve chromosomal changes, specifically a gain of 12p. All 
invasive TGCTs show overrepresentation of 12p, and up to 80% have an 
isochromosome of 12p. This gain of 12p is not detected in CIS cells, indicating that gain 
of 12p is an important step in tumor progression. One possibility is that gain of 12p is 
involved in tumor cell growth independence from Sertoli cells, consistent with 
observations that gain of 12p is already present in intratubular seminomas, which have 
lost their interactions with Sertoli cells but are still pre-invasive. In addition, embryonic 
stem (ES) cell lines with a gain of chromosome 12 gain a growth advantage in culture. 
Various candidate genes have been investigated on 12p, including KRAS, CCND2, 
NANOG, and STELLAR, but currently it is thought that multiple genes are involved in 
the development of invasive seminomas from CIS cells(72). 
The observed OCT4 expression(72, 160) in these seminoma cells was significant 
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because historically OCT4 was thought to be expressed only by embryonic germ cells in 
humans, leading to the conclusion that seminomas must arise from embryonic germ 
cells.  However, recently it has been shown that OCT4 is in fact expressed in the human 
adult testis(183). OCT4 expression is not exclusive to embryonic germ cells, but is also 
expressed by a subset of spermatogonia in the human testis, consistent with the OCT4 
expression pattern in mice(23), where the undifferentiated spermatogonia express 
OCT4. These new data indicate that seminomas could arise from postnatal OCT4 
expressing spermatogonia or embryonic germ cells.  
Another observation in support of an embryonic germ cell origin of seminomas is 
the biallelic expression of two genetically imprinted genes H19 and IGF2 in these 
tumors(181).  In the male germline of both mouse and humans, the germ cells undergo 
a genome-wide demethylation after their arrival in the embryonic gonad and then begin 
to re-establish the imprinting methylation marks in these gonadal germ cells.  In mice, 
these methylation marks are not completed until after birth in differentiating 
spermatogonia(184, 185). When complete, these marks result in H19 expression only 
from the maternal allele and IGF2 expression only from the paternal allele. Biallelic 
expression of H19 and IGF2 is consistent with embryonic germ cells that have erased 
but not re-established their imprinting methylation marks, leading to the conclusion that 
seminomas derive from embryonic germ cells. However biallelic expression may not be 
specific to embryonic germ cells, as the methylation marks thought to establish the 
monoallelic expression of imprinted genes are not completed until after birth in 
mice(184, 185). It is unclear when biallelic expression ceases in the germ cells as this 
expression has not been studied directly, only indirectly through the methylation status 
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of the cells. It is also not known whether the methylation marks directly correlate with 
loss of biallelic expression.  Further characterization of the expression of these 
imprinted genes is necessary in order to determine if biallelic expression is specific to 
embryonic germ cells. Additionally, it is important to note that these temporal studies of 
imprinted genes have been characterized in mice. It is not known if the timing of these 
mechanisms in human germ cells are consistent with the timing observed in mouse. 
These observations lead me to question whether human seminomas could 
originate from SSCs or early postnatal spermatogonial cells retaining SSC potential. In 
humans, SSCs are known to express OCT4, AP, and SSEA4 similar to seminomas, but 
do not have high telomerase activity and methylation analysis has shown androgenic 
imprinting (although these are not completely methylated). However, when human 
SSCs are cultured, they lose imprinting methylation marks, increase telomerase activity, 
and express NANOG and STELLAR (186, 187). These results indicate that postnatal 
spermatogonial cells can adopt embryonic germ cell characteristics in culture, 
suggesting that transformation of these cells could have a similar effect. These 
observations lead me to propose an alterative hypothesis for the cell of origin of human 
seminomas. I propose that human seminomas can originate from transformed SSCs, 
who have been reprogrammed into an embryonic germ cell fate.  
In support of this proposed cell of origin are two mouse SSC models, the GDNF-
overexpression mouse, and transplanted SSCs with either activated RAS or 
overexpression of CCND2/CCNE1. Both of these mouse models have a defect in SSC 
differentiation, which leads to the development of seminomatous tumors. The GDNF-
overexpression seminomas, like human seminomas, are aneuploid, and alkaline 
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phosphatase reactive(105). The seminoma tumors that formed from transplanted SSCs 
with activated RAS and those overexpressing CCND2/CCNE1 both were also shown to 
express placental alkaline phosphatase(188). These tumors all originate from clusters of 
spermatogonia in animals within the first month, but no CIS cells are observed, the cell 
type thought to be the cell of origin in human seminoma. 
This ability of SSCs to regain pluripotency by reprogramming to an ES cell-like 
state may explain the observed switch in fate of seminoma tumors into nonseminomas. 
While seminomas are a homogeneous tumor, nonseminomas are highly 
heterogeneous, displaying various stages of differentiation, including somatic tissue 
types and extra-embryonic tissue types(72). The reprogramming of SSCs may result 
from KLF4 expression, a gene known to play an important role in both iPS (induced 
pluripotent cells) and ES cells, which is normally absent in spermatogonia but its 
expression is found in CIS cells and seminoma cells(189). SSC independence from 
Sertoli cells and invasive behavior may involve de-regulation of GDNF signaling, as 
seminoma cells express GDNF and Ret, GDNF’s receptor(190). 
 
Stra8-deficient spermatogonial tumors 
The Stra8-deficient spermatogonial tumors present an interesting possible animal 
model for human seminoma. These Stra8-deficient spermatogonial tumors arise from a 
defect in the differentiation of undifferentiated spermatogonia, cells that retain SSC 
potential. This differentiation defect leads to an accumulation of undifferentiated 
spermatogonia, and the formation of clusters of these cells. The clusters continue to 
expand within the basal compartment as the cells proliferate, eventually breaking out of 
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the basal compartment and the tubule itself, forming testicular tumors.  
We looked at the expression of Stra8-deficient spermatogonial tumors to see if 
an embryonic germ cell origin is supported. The Stra8-deficient spermatogonial tumors 
do express Oct4 (Chapter 3, Figure 2), an important diagnostic marker for human 
seminoma, but as previously stated, Oct4 expression is not specific to embryonic germ 
cells(23).  In addition, genes expressed in embryonic but not in postnatal male germ 
cells, Nanog and Dppa3(150), are not expressed in Stra8-deficient spermatogonial 
tumors compared to the expression in E13.5 germ cells (Chapter 3, Figure 2).  This 
indicates that the Stra8-deficient spermatogonial tumors do not originate from an 
embryonic germ cell. The Stra8-deficient spermatogonial tumors do express markers of 
undifferentiated spermatogonia but do not express markers of spermatocytes (Chapter 
3, Figure 2), indicating that these tumors arise from undifferentiated spermatogonia. In 
support of this, preliminary microRNA expression data of Stra8-deficient spermatogonial 
tumors was consistent with microRNA expression of germline stem cells (unpublished 
data, Michelle Carmell). Interestingly, the Stra8-deficient spermatogonial tumors also 
express LIN28, a gene known to regulate the processing of mature Let7 microRNAs, 
and to act in the reprogramming of terminally differentiated cells into pluripotent cells. 
The precursor clusters of cells also express LIN28, indicating that Lin28 function could 
be part of the pathogenesis of Stra8-deficient spermatogonial tumors. LIN28 is 
associated with advanced human malignancies and is thought to promote 
transformation(191). Further work is needed to assess whether Lin28 promotes 
transformation of undifferentiated spermatogonia in Stra8-deficient spermatogonial 
tumors. 
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The Stra8-deficient spermatogonial tumors are dependent on Ccnd2 (Chapter 3, 
Figure 5), a finding consistent with the 12p isochromosome formation found consistently 
in human seminoma, where Ccnd2 is located in the human genome. CCND2 is also 
expressed by CIS cells and invasive seminoma cells(72), leading Oosterhuis and 
Looijenga to speculate that Ccnd2 plays a role in the pathogenesis of human 
seminoma. In mouse SSC, if Ras is activated, which results in an increase in CCND2 
and CCNE1 expression in these cells, or CCND2 and CCNE1 are overexpressed 
directly together, transplanting these SSC results in spermatogonial tumors. This 
indicates an oncogenic role for Ccnd2 in SSC. Interestingly, this oncogenic role is 
specific to CCND2, as CCND1 and CCND3 overexpression did not result in 
spermatogonial tumors. This would be consistent with the specific induction of Ccnd2 
expression in the Stra8-deficient spermatogonial tumors, as compared to Ccnd1 and 
Ccnd3 expression. Further investigations of the Ccnd2 requirement in Stra8-deficient 
spermatogonial tumor formation are necessary in order to unravel possible mechanisms 
for Ccnd2 function in Stra8-deficient spermatogonial tumor formation and in human 
seminoma. 
Seminomas are proposed to originate from embryonic germ cells based on gene 
expression in CIS cells, the predicted precursor to these tumors based on correlation 
with tumor incidence, and expression, telomerase activity, and imprinting status in 
seminoma cells. We propose that while these observations are consistent with an 
embryonic germ cell origin for these tumors, based on the arguments above they are 
also consistent with a transformed SSC as the cell of origin. The mouse models of 
defective SSC differentiation that lead to seminomatous tumors forming serve as proof 
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of principle that SSCs can act as a cell of origin of human seminoma. In addition, the 
Stra8-deficient spermatogonial tumors show that the human counterpart to the 
undifferentiated spermatogonia population in mouse can act as the cell of origin of 
human seminoma. These observations lead us to question whether other models of 
defective SSC differentiation also form spermatogonial tumors. 
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Appendix 2 
 
 
 
Stra8 is required for testicular teratomas to form 
in 129Sv/S4Jae males. 
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The following appendix describes an additional finding of Stra8 function in a 
different TGCT type than the seminomas discussed in Appendix 1, the teratomas. 
Teratomas are a type of testicular germ cell tumor that form in human newborns and 
infants. These tumors are the most common solid tumors found in newborns. 
Teratomas are composed of tissue from each of the three germ layers, ectoderm, 
mesoderm, and endoderm, and are thought to arise from a PGC or EC cell that 
differentiated into these tissue types. A similar tumor, the teratocarcinoma, also retains 
some undifferentiated PGCs or EC cells in addition to the germ layer tissues. The PGC 
origin of these tumors is based on the pattern of genomic imprinting in these tumors. 
During germ cell development the germ cells undergo genome-wide demethylation, 
which erases the inherited biparental imprinting marks. The teratoma tumors cells were 
found to be partially erased for these marks, indicating that they originate from a germ 
cell still undergoing this erasure, a PGC. The pathogenesis of these tumors is distinct 
from the pathogenesis of seminomas, who are also proposed to originate from an 
embryonic germ cell (see Appendix 1), in that teratomas/teratocarcinomas are not 
associated with CIS cells, nor do they develop 12p isochromosomes(97). 
 An animal model for these tumors is found in the inbred 129 strain of mice, which 
form testicular teratomas spontaneously in 1-10% of males(97, 98). Using this animal 
model, it was determined that the teratomas that form do arise from PGCs with either 
disturbed maturation or apoptosis, consistent with a PGC origin of human teratomas. 
The teratomas that form on the inbred 129 strain have been intensely studied in order to 
discover susceptibility and modifier genes, which could give insight into how teratomas 
form in humans. Susceptibility genes are required, while modifier genes are not required 
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but rather affect the rate of progression or severity.  To date, no susceptibility genes 
have been found, however several modifier genes have been characterized.  
 Some of the known modifier genes include Pten, Trp53, Apobec1, Ay, Kitl, and 
Dnd1. The most well-known modifier is Dnd1, a gene recently discovered to be 
responsible for the Ter mutation. The Ter mutation is a semi-dominant allele of Dnd1 
causing a premature stop codon(99) that arose spontaneously in the 129 mice and 
enhances teratoma incidence dramatically. Heterozygous carriers (Dnd1Ter) of the 
mutation have a 17% incidence, while homozygotes (Dnd1Ter/Ter) have a 94% 
incidence(100). Dnd1 is important for PGC survival as Dnd1Ter/Ter embryos have 
approximately ten PGCs and are infertile as adults(101). Interestingly this effect of Dnd1 
is genetic background specific, as Dnd1Ter/Ter mice only form teratomas on the inbred 
129 strain(102, 103).  
 In order to study effect of genetic background on the Stra8-deficient testicular 
germ cell phenotypes, we crossed the Stra8 mutation onto the inbred 129 strain. Given 
the known tumorigenic properties of this strain, we predicted the Stra8-deficient 
spermatogonial tumor incidence would be increased or the latency would be decreased 
on this genetic background. Surprisingly, as shown in Chapter 3, Table 1, the 
spermatogonial tumor incidence was found to be decreased on the inbred 129 strain as 
compared to the inbred C57BL6 strain. Consistent with the wildtype inbred C57BL6 
testes, the wildtype inbred 129 testes did not form spermatogonial tumors. However, the 
wildtype inbred 129 testes did form testicular teratomas as reported in the literature for 
this inbred strain. Interestingly, the Stra8-deficient inbred 129 testes did not form 
122
testicular teratomas (Table 1). We conclude that Stra8 is required for testicular teratoma 
formation on the inbred 129 strain, the first susceptibility gene known. 
 
Table 1. Teratoma Incidence on 129 mice 
                                                                        Stra8 Genotype 
 Wildtype Stra8-deficient 
Teratoma Incidence N5 and N10 8/45  (18%) 0/20 
Teratoma Incidence N10 only 2/23 (1%) 0/7 
  
At first glance this result is perplexing because the testicular teratomas originate 
from embryonic male germ cells, a cell type that does not express Stra8. In fact it 
appears that great care is taken to ensure that embryonic male germ cells do not 
express Stra8. Studies of RA in the embryonic gonads have revealed a mechanism of 
RA degradation in the male embryonic testis driven by Cyp26b1, a p450 enzyme. It is 
thought that Cyp26b1 expression in the embryonic testes prevents RA signaling and 
Stra8 expression in the germ cells. A second mechanism postulated to deter RA 
signaling after Cyp26b1 expression is lost, is controlled by Nanos2. In the absence of 
either Cyp26b1 or Nanos2, the germ cells are exposed to RA and express Stra8. The 
consequence of this expression is aberrant entry into meiosis and continued mitotic 
division, with eventual apoptosis and loss of germ cells. Unfortunately, these mice die 
shortly after birth, so it is unknown whether these aberrant germ cells are tumorigenic. 
The requirement for Stra8 in testicular teratoma formation, and the continued mitotic 
proliferation followed by germ cell loss in Stra8-expressing embryonic male germ cells 
suggests that expression of Stra8 could be part of teratoma pathogenesis.  
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